<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anesthesia for craniotomy in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anesthesia for craniotomy in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anesthesia for craniotomy in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Chanannait Paisansathan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mehmet S Ozcan, MD, FCCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey J Pasternak, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marianna Crowley, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H8563925">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Craniotomy is performed for a variety of indications, including tumor resection, intracranial vascular procedures, evacuation of hematoma, and trauma.
        </p>
        <p>
         This topic will discuss overall anesthetic management for craniotomy. Anesthetic management for some specific types of craniotomy is discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/114423.html" rel="external">
          "Anesthesia for posterior fossa craniotomy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/94284.html" rel="external">
          "Anesthesia for intracranial neurovascular procedures in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/94288.html" rel="external">
          "Anesthesia for awake craniotomy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H75134162">
         <span class="h1">
          PREOPERATIVE EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the purpose of preoperative evaluation, craniotomies may be considered moderate- to high-risk procedures, depending on the procedure performed [
         <a href="#rid1">
          1,2
         </a>
         ]. Preoperative evaluation and testing prior to anesthesia are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/94539.html" rel="external">
          "Preoperative evaluation for anesthesia for noncardiac surgery"
         </a>
         .)
        </p>
        <p>
         The following are issues of particular concern for craniotomy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic status
         </strong>
         –
         <strong>
         </strong>
         In addition to the usual preanesthesia evaluation, we focus on preoperative neurologic status, including current and prior deficits, signs and symptoms of increased intracranial pressure (ICP), and history of seizures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiopulmonary status
         </strong>
         –
         <strong>
         </strong>
         Preoperative cardiac evaluation may be of particular concern for patients who are at high risk of venous air embolism (VAE; eg, surgery in the sitting position, surgery near venous sinuses). Evaluation and risk assessment in this setting are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/114424.html" rel="external">
          "Intraoperative venous air embolism during neurosurgery", section on 'Risk of paradoxical embolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antiseizure medications
         </strong>
         – Many patients who undergo craniotomy are taking antiseizure medications, which can affect metabolism of a variety of drugs, including neuromuscular blocking agents (NMBAs). Patients should be instructed to take the usual dose on the morning of surgery, unless the patient is to undergo seizure focus mapping. For more detailed information on potential drug-drug interactions, refer to the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         within UpToDate.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Glucocorticoids
         </strong>
         – For patients taking glucocorticoids preoperatively, stress doses may be required before induction of anesthesia and blood glucose may be elevated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anticoagulants
         </strong>
         – In most cases,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , nonsteroidal anti-inflammatory drugs (NSAIDS), and other medications that affect coagulation should be discontinued in advance of craniotomy. (See
         <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">
          "Perioperative medication management", section on 'Medications affecting hemostasis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory evaluation
         </strong>
         –
         <strong>
         </strong>
         Preoperative blood testing should be based on patient factors and the extent of the planned procedure. We usually perform a complete blood count, measure blood glucose and electrolytes, and send a blood type and screen, in addition to any testing indicated by patient comorbidities. We crossmatch for blood products if there is a high risk of hemorrhage (eg, pathology involving cerebral sinuses, highly vascular intracranial tumors). (See
         <a class="medical medical_review" href="/z/d/html/94539.html" rel="external">
          "Preoperative evaluation for anesthesia for noncardiac surgery", section on 'Preoperative testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H567773710">
         <span class="h1">
          PREMEDICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Premedication for craniotomy should be individualized based on the patient's level of anxiety, baseline neurologic status, and comorbidities. Patients with intracranial pathology may be especially sensitive to sedatives and opioids; premedication should be titrated to effect using small doses of medication (eg,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         1 to 2 mg intravenous [IV], administered in 0.5 mg increments). For patients with increased intracranial pressure (ICP), we withhold sedation until the patient is fully monitored in a setting that would allow immediate airway management.
        </p>
        <p class="headingAnchor" id="H1228133176">
         <span class="h1">
          ANESTHETIC MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         General endotracheal anesthesia is the preferred technique for craniotomy, though for specific indications, the procedure can be performed awake. (See
         <a class="medical medical_review" href="/z/d/html/94288.html" rel="external">
          "Anesthesia for awake craniotomy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H652880072">
         <span class="h2">
          General concerns
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following issues that affect anesthetic management should be addressed before any craniotomy, in consultation with the surgeon:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Need for brain relaxation, including dose and timing of the necessary medications (see
         <a class="local">
          'Planned brain relaxation'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient positioning (see
         <a class="local">
          'Positioning'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Risk of venous air embolism (VAE) (see
         <a class="medical medical_review" href="/z/d/html/114424.html" rel="external">
          "Intraoperative venous air embolism during neurosurgery"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood pressure (BP) goals and anticipated need for changes during surgery (see
         <a class="local">
          'Goal for intraoperative blood pressure'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Need for and doses of antiseizure medications (see
         <a class="local">
          'Antiseizure drugs'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of neuromonitoring (see
         <a class="medical medical_review" href="/z/d/html/91216.html" rel="external">
          "Neuromonitoring in surgery and anesthesia"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2098211324">
         <span class="h2">
          Variable surgical stimulus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Craniotomy involves periods of intense, painful stimulus separated by relatively long periods of low-level stimulation. Skull pinning is a brief, intensely painful stimulus. Skin incision, raising the bone flap, and opening the dura are also particularly painful, and may require adjustment of anesthetic depth. These painful events are often separated by periods of low stimulation during positioning and performing intracranial brain dissection.
        </p>
        <p>
         Although not as stimulating as incision and opening, wound closure is also painful and may take as long as an hour. Opioids,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , and/or antihypertensive medication may be required as the anesthetic is lightened for emergence.
        </p>
        <p class="headingAnchor" id="H1965851932">
         <span class="h3">
          Skull pinning
         </span>
         <span class="headingEndMark">
          —
         </span>
         Options for minimizing hypertension and tachycardia during skull pinning include administration of intravenous (IV) medications (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         or
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ), use of local anesthetic infiltration at the pin sites, or use of scalp blocks.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          IV pretreatment
         </strong>
         – Timing of pinning should be coordinated with the surgeon to allow effective pretreatment. We usually administer
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         0.5 to 1 mg/kg IV and opioid (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         100 mcg IV or
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         50 mcg IV) approximately one minute prior to pinning. A small dose of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         (eg, 20 to 50 mg IV) may be added depending on the patient's hemodynamic status and risk factors for subsequent hypotension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Typical doses of IV drugs used in anticipation of pinning include
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         50 to 100 mcg or
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         25 to 50 mcg,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         20 to 50 mg,
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         0.25 to 0.5 mg/kg,
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         1 mg/kg, or
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          nicardipine
         </a>
         0.5 to 1 mg IV [
         <a href="#rid3">
          3-6
         </a>
         ]. Higher doses of opioids can result in hypotension after the stimulus of pinning is over, particularly if administered with propofol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Scalp blocks
         </strong>
         –
         <strong>
         </strong>
         In some institutions, scalp blocks are placed prior to skull pinning to provide analgesia for pinning, skin incision, and closure, as well as postoperative analgesia [
         <a href="#rid7">
          7,8
         </a>
         ]. The blocks can be placed before or after induction of anesthesia and may ameliorate the hemodynamic response to skull pinning. In some institutions they are placed at the end of surgery before emergence from anesthesia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One single-institution randomized trial evaluated scalp blocks versus standard care in 60 patients who underwent supratentorial craniotomy [
         <a href="#rid9">
          9
         </a>
         ]. Scalp blocks resulted in lower mean arterial pressure (MAP) and heart rate during skull pinning and skin incision, reduced
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         doses during the procedure, reduced postoperative pain scores, and modestly reduced opioid consumption in the first two postoperative days. (See
         <a class="local">
          'Postoperative pain control'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8564068">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Standard physiologic monitors may be sufficient for select minimally invasive craniotomies (eg, burr holes for subdural hematoma evacuation). In most cases, additional monitoring is indicated. (See
         <a class="medical medical_review" href="/z/d/html/100067.html" rel="external">
          "Basic patient monitoring during anesthesia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arterial catheter
         </strong>
         –
         <strong>
         </strong>
         An arterial catheter is placed for most craniotomies for continuous BP monitoring and to facilitate blood sampling for blood gases and electrolytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring for venous air embolism
         </strong>
         –
         <strong>
         </strong>
         Monitors for VAE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/114424.html" rel="external">
          "Intraoperative venous air embolism during neurosurgery", section on 'Monitoring for venous air embolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central venous catheter (CVC)
         </strong>
         – CVCs are not routinely placed for craniotomy unless required for venous access or for possible air aspiration during VAE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuromonitoring
         </strong>
         – Intraoperative electroencephalography (EEG) and evoked potential monitoring during craniotomy have implications for the choice of anesthetic medication. These monitoring modalities are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/91216.html" rel="external">
          "Neuromonitoring in surgery and anesthesia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Intraoperative intracranial pressure (ICP) monitoring is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94283.html" rel="external">
          "Anesthesia for patients with acute traumatic brain injury", section on 'Monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8564106">
         <span class="h2">
          Induction of anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Goals for induction of anesthesia for craniotomy include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic stability
         </strong>
         –
         <strong>
         </strong>
         Drugs and doses should be selected to maintain cerebral perfusion pressure (CPP) while avoiding hypertension and the risk of intracranial hemorrhage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoiding increase in ICP
         </strong>
         – Medication and ventilation should be managed to avoid increase in ICP, especially for patients with preoperative increased ICP.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H78577820">
         <span class="h3">
          Choice of induction agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Induction agents should be chosen based on patient factors and the effects of the agents on cerebral physiology. With the exception of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , IV induction agents cause reductions in both cerebral metabolic rate (CMR) and cerebral blood flow (CBF), resulting in no change or decrease in ICP  (
         <a class="graphic graphic_table graphicRef105673" href="/z/d/graphic/105673.html" rel="external">
          table 1
         </a>
         ). Autoregulation and responsiveness to carbon dioxide (CO
         <sub>
          2
         </sub>
         ) are preserved. (See
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults", section on 'Physiology'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Propofol
         </strong>
         – CMR, CBF, cerebral blood volume (CBV), and ICP are reduced with induction doses of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         [
         <a href="#rid10">
          10,11
         </a>
         ], and autoregulation and CO
         <sub>
          2
         </sub>
         responsiveness are preserved [
         <a href="#rid12">
          12
         </a>
         ]. Propofol can induce an isoelectric EEG. The induction dose should be adjusted for patient factors. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Propofol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Barbiturates
         </strong>
         – Barbiturates cause a dose-dependent reduction in CMR, CBF, and ICP, while autoregulation and CO
         <sub>
          2
         </sub>
         responsiveness are maintained [
         <a href="#rid13">
          13-15
         </a>
         ]. Thiopental (available outside the United States) can produce an isoelectric EEG; by contrast,
         <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">
          methohexital
         </a>
         activates seizure foci. Barbiturates can cause hypotension, though (at an equivalent dose) to a lesser extent than
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Methohexital'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etomidate
         </strong>
         –
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          Etomidate
         </a>
         does not usually decrease BP or cardiac output; an induction dose decreases CBF and CMR and reduces ICP without adversely impacting CPP [
         <a href="#rid16">
          16-18
         </a>
         ], while preserving CO
         <sub>
          2
         </sub>
         responsiveness [
         <a href="#rid16">
          16
         </a>
         ]. However, even with a single induction dose, etomidate inhibits corticosteroid production in the adrenal gland for up to 24 hours [
         <a href="#rid19">
          19,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Etomidate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The effects of
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         on cerebral vasculature are complex. In animal models, etomidate is a cerebral vasoconstrictor, possibly mediated by mitochondrial dysfunction and inhibition of nitric oxide synthase [
         <a href="#rid21">
          21-23
         </a>
         ]. A study of human brain tissue oxygenation during intracranial aneurysm surgery reported that administration of etomidate at a dose that produced EEG burst suppression resulted in a 30 percent reduction in tissue partial pressure of oxygen (PO
         <sub>
          2
         </sub>
         ), with a further 32 percent reduction of PO
         <sub>
          2
         </sub>
         during temporary artery clipping [
         <a href="#rid24">
          24
         </a>
         ]. Because of these studies, we avoid administration of etomidate for induction of anesthesia for patients with cerebral vasospasm or other conditions associated with cerebral ischemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          Etomidate
         </a>
         is associated with a higher rate of postoperative nausea and vomiting (PONV) than other induction agents [
         <a href="#rid25">
          25,26
         </a>
         ], which is a disadvantage in patients undergoing craniotomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ketamine
         </strong>
         – Data regarding the effect of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         on cerebral physiology are conflicting. Some human and animal studies have reported that ketamine increases CBF, CMR, and ICP [
         <a href="#rid27">
          27-31
         </a>
         ]. By contrast, other studies have reported no change or a decrease in these parameters, particularly when ketamine is administered with other anesthetics [
         <a href="#rid32">
          32-36
         </a>
         ]. Given the uncertainty, we believe that ketamine should be used with caution for craniotomy, especially for patients with increased ICP. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Ketamine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H78577951">
         <span class="h3">
          Opioids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Opioids cause minimal effects on cerebral physiologic parameters as long as MAP is maintained [
         <a href="#rid37">
          37-39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Opioids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H100616172">
         <span class="h3">
          Lidocaine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          Lidocaine
         </a>
         1 to 1.5 mg/kg IV may be administered during induction of anesthesia to suppress the cough reflex during laryngoscopy and to blunt, but not eliminate, the hemodynamic response to intubation [
         <a href="#rid40">
          40,41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Lidocaine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H78577983">
         <span class="h3">
          Neuromuscular blocking agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nondepolarizing neuromuscular blocking agents (NMBAs) have no direct effects on cerebral physiology. Less commonly used NMBAs that are associated with histamine release at higher or rapid doses (ie,
         <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">
          atracurium
         </a>
         , mivacurium [outside the United States]) can theoretically cause a reduction in CPP because of a decrease in MAP, cerebral vasodilation, and an increase in ICP [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Atracurium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Mivacurium'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          Succinylcholine
         </a>
         can produce a transient increase in ICP, possibly the result of an increase in CBF related to the arousal response to muscle fasciculations [
         <a href="#rid43">
          43
         </a>
         ]. However, the brief increase in ICP with succinylcholine can be attenuated by administration of a defasciculating dose of a nondepolarizing NMBA [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         For rapid sequence induction and intubation (RSII) in patients in whom ICP is a concern, we administer a defasciculating dose of nondepolarizing NMBA (eg,
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         2 mg IV,
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         1.5 mg IV, or
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         0.3 mg IV) followed by
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         1.5 to 2 mg/kg IV. For RSII when succinylcholine is contraindicated (eg, burns, denervation injury), we administer rocuronium 1 mg/kg IV or high-dose
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         (
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         2 to 2.5 mg/kg IV followed by
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         10 mg IV and remifentanil 3 to 5 mcg/kg IV) [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">
          "Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Neuromuscular blocking agents (NMBAs)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H336686064">
         <span class="h2">
          Positioning
         </span>
         <span class="headingEndMark">
          —
         </span>
         Positioning for craniotomy requires meticulous attention to detail to avoid nerve damage, skin pressure injury, cervical spine injury, and damage to the eyes. These procedures can be performed in a variety of positions, including supine, prone, lateral or semilateral (Park Bench), and sitting or semisitting. The head is usually held in skull pins attached to a head frame and is often turned to the side, sometimes with the neck flexed.
        </p>
        <p>
         General concerns related to positioning, including potential nerve or skin damage and physiologic effects of various positions, are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/94593.html" rel="external">
          "Patient positioning for surgery and anesthesia in adults"
         </a>
         .)
        </p>
        <p>
         Some issues specific to craniotomy include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cervical spine injury
         </strong>
         –
         <strong>
         </strong>
         If the patient will be positioned with the head rotated or the neck flexed, the patient's neck range of motion should be examined preoperatively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Excessive neck flexion
         </strong>
         –
         <strong>
         </strong>
         Neck flexion can kink the endotracheal tube (ETT) during positioning and/or later during the case when the ETT warms or with minor head movement. A wire-reinforced (armored) ETT can be used if kinking is a particular concern. Additionally, excessive neck flexion can impair venous drainage from the brain, contributing to increased surgical site bleeding or brain edema. Tongue edema can also occur as a result of excessive neck flexion. Reducing the degree of neck flexion can help mitigate these adverse effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VAE
         </strong>
         –
         <strong>
         </strong>
         VAE is a risk whenever the operative site is above the level of the heart, and this risk is higher during surgery around venous sinuses. For craniotomy, most patients are positioned somewhat head-up to facilitate venous drainage and brain relaxation. (See
         <a class="medical medical_review" href="/z/d/html/114424.html" rel="external">
          "Intraoperative venous air embolism during neurosurgery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pneumocephalus
         </strong>
         –
         <strong>
         </strong>
         Supratentorial pneumocephalus (STP) can develop during procedures performed in the sitting position as cerebrospinal fluid (CSF) drains out of the cranial cavity at the durotomy site. In a series of 106 consecutive patients that underwent sitting craniotomy, 42 percent had postoperative STP detected on a computed tomography (CT) scan, with volumes ranging from 6 to 280 mL [
         <a href="#rid46">
          46
         </a>
         ]. Six patients in this series had intraoperative somatosensory evoked potential (SSEP) changes (ie, reduction in signal amplitude) that were attributed to STP, all of which measured greater than 90 mL in volume on postoperative CT scan.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If symptomatic or associated with loss of intraoperative SSEP signals, STP is usually referred to as "tension pneumocephalus." Tension pneumocephalus can result in delayed emergence from anesthesia, locked-in syndrome, and lateral rectus muscle palsy [
         <a href="#rid47">
          47-52
         </a>
         ], and requires emergent evacuation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8564131">
         <span class="h2">
          Maintenance of anesthesia
         </span>
        </p>
        <p class="headingAnchor" id="H1091124055">
         <span class="h3">
          Choice of anesthetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of medications for maintenance of anesthesia for craniotomy should be based on the degree of preexisting intracranial hypertension, the need for brain relaxation during surgery, the use of neuromonitoring, and the patient's medical issues.
        </p>
        <p>
         Anesthetics can affect cerebral physiology through changes in cerebral metabolism and blood flow either directly or indirectly by changing ICP and CPP  (
         <a class="graphic graphic_table graphicRef105673" href="/z/d/graphic/105673.html" rel="external">
          table 1
         </a>
         ). In many cases, a balanced anesthetic including relatively low doses of the potent inhalation anesthetics (ie,
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          isoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">
          desflurane
         </a>
         , or halothane [where available]), with or without
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O), and opioids is appropriate; for patients with elevated ICP, we suggest using a predominantly IV technique [
         <a href="#rid11">
          11
         </a>
         ]. A strategy for anesthesia during neuromonitoring is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/91216.html" rel="external">
          "Neuromonitoring in surgery and anesthesia", section on 'Anesthetic strategy'
         </a>
         .)
        </p>
        <p>
         There is no consensus on the ideal anesthetic regimen (ie, total intravenous anesthesia [TIVA] versus inhalation anesthesia) for elective craniotomy in the absence of elevated ICP. A meta-analysis including 14 studies with over 1800 patients who underwent craniotomy reported various outcome measures for TIVA compared with inhalation anesthesia [
         <a href="#rid53">
          53
         </a>
         ]. ICP was approximately 5 mmHg lower and CPP approximately 16 mmHg higher with TIVA than with inhalation anesthesia, with no difference in operative conditions after dural opening, recovery profiles, postoperative complications, or neurologic outcome.
        </p>
        <p class="headingAnchor" id="H258395315">
         <span class="h4">
          Potent inhalation agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         The potent, halogenated inhalation anesthetics (ie,
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          isoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">
          desflurane
         </a>
         , halothane [where available]) are all dose-dependent cerebral vasodilators.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At doses below 1 minimum alveolar concentration (MAC), they reduce CMR and do not abolish coupling of CMR and CBF, such that without other contributing factors there is a net modest decrease in CBF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At doses above 1 MAC, these agents disrupt cerebral autoregulation and vasodilation predominates, leading to a gradual increase in CBF and CBV with increasing doses [
         <a href="#rid54">
          54-59
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The degree to which the potent inhalation agents decrease CMR varies. At MAC-equivalent doses, reduction in CMR and therefore CBF in order of decreasing potency is as follows:
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         &gt;
         <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">
          desflurane
         </a>
         and
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          isoflurane
         </a>
         &gt; halothane [
         <a href="#rid54">
          54-58,60,61
         </a>
         ]. In one small study in healthy volunteers, sevoflurane reduced CMR to a similar degree as
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         at equal depth of anesthesia; however, propofol reduced CBF more than sevoflurane [
         <a href="#rid61">
          61
         </a>
         ]. These results support a preference for TIVA rather than inhalation anesthetics (particularly at high doses) for patients with increased ICP or for whom significant brain relaxation will be required. However, if inhalation anesthesia is used, sevoflurane would be our preferred agent based on its more favorable profile on CMR and CBF. (See
         <a class="local">
          'Choice of anesthetics'
         </a>
         above.)
        </p>
        <p>
         Responsiveness to CO
         <sub>
          2
         </sub>
         is maintained during administration of volatile anesthetics [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H258395389">
         <span class="h4">
          Nitrous oxide
         </span>
         <span class="headingEndMark">
          —
         </span>
         N
         <sub>
          2
         </sub>
         O can cause increases in CBF, CMR, and ICP. Autoregulation in response to changes in CO
         <sub>
          2
         </sub>
         appears to be preserved when N
         <sub>
          2
         </sub>
         O is administered [
         <a href="#rid63">
          63,64
         </a>
         ]. The magnitude of changes in cerebral physiology with N
         <sub>
          2
         </sub>
         O is affected by the administration of other anesthetic drugs and by ventilation, as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          N
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          O alone
         </strong>
         –
         <strong>
         </strong>
         N
         <sub>
          2
         </sub>
         O alone can cause substantial increases in ICP and CBF in patients without intracranial pathology [
         <a href="#rid65">
          65
         </a>
         ] and in patients with intracranial tumors [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          N
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          O with IV anesthetics
         </strong>
         – Concomitant administration of IV anesthetic medications can blunt the increase in CBF that occurs with N
         <sub>
          2
         </sub>
         O alone. Studies of CBF when N
         <sub>
          2
         </sub>
         O was added to anesthesia with barbiturates [
         <a href="#rid67">
          67,68
         </a>
         ], opioids [
         <a href="#rid69">
          69
         </a>
         ], benzodiazepines, and
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         [
         <a href="#rid70">
          70
         </a>
         ] have reported minimal or no increase in CBF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          N
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          O with volatile anesthetics
         </strong>
         –
         <strong>
         </strong>
         When added to anesthesia with a volatile inhalation anesthetic (ie,
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          isoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">
          desflurane
         </a>
         , or halothane), N
         <sub>
          2
         </sub>
         O can result in a substantial increase in CBF. As an example, one study that compared CBF during 1.5 MAC isoflurane anesthesia with 0.75 MAC isoflurane and 65 percent N
         <sub>
          2
         </sub>
         O reported 43 percent greater CBF with the anesthetic that included N
         <sub>
          2
         </sub>
         O [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, whereas N
         <sub>
          2
         </sub>
         O increases CBF, it does not increase CBV when used along with a volatile anesthetic. As CBV is a greater determinant of ICP than CBF, N
         <sub>
          2
         </sub>
         O is not necessarily contraindicated during craniotomy in patients with concerns for significant elevations in ICP [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          N
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          O with hyperventilation
         </strong>
         – Since autoregulation is preserved, hyperventilation can prevent an increase in CBF during N
         <sub>
          2
         </sub>
         O anesthesia [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         N
         <sub>
          2
         </sub>
         O may expand the gas content of air-filled spaces. If N
         <sub>
          2
         </sub>
         O was not used during anesthesia, it should not be started following dural closure because of potential expansion of intracranial air. If N
         <sub>
          2
         </sub>
         O has been used for the duration of the anesthetic, N
         <sub>
          2
         </sub>
         O is unlikely to expand intracranial gas after dural closure, as the residual gas would already include N
         <sub>
          2
         </sub>
         O.
        </p>
        <p>
         We avoid using N
         <sub>
          2
         </sub>
         O in patients who have recently had a craniotomy, due to concerns for potential expansion of any residual intracranial gas. It is unclear how long N
         <sub>
          2
         </sub>
         O should be avoided after craniotomy, though residual air may last several weeks [
         <a href="#rid72">
          72
         </a>
         ]. One contributor to this topic takes a conservative approach and waits eight weeks.
        </p>
        <p class="headingAnchor" id="H258395408">
         <span class="h4">
          Intravenous anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         IV anesthetics are commonly used as part of a balanced anesthetic that includes inhalation agents, or as TIVA. IV anesthetics are discussed in detail separately. Issues specific to craniotomy are discussed here. (See
         <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">
          "Maintenance of general anesthesia: Overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">
          "Maintenance of general anesthesia: Overview", section on 'Total intravenous anesthesia'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Propofol
         </strong>
         <strong>
          infusion
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         infusion causes reduction in CMR, CBF, CBV, and ICP [
         <a href="#rid61">
          61,73,74
         </a>
         ], while CO
         <sub>
          2
         </sub>
         responsiveness and autoregulation are maintained [
         <a href="#rid12">
          12,75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Opioids
         </strong>
         –
         <strong>
         </strong>
         When administered as part of IV anesthesia with controlled ventilation, opioids have minimal, clinically irrelevant effects on cerebral physiology [
         <a href="#rid69">
          69,76,77
         </a>
         ].
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          Morphine
         </a>
         may cause histamine release in some patients, which could increase CBF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dexmedetomidine
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          Dexmedetomidine
         </a>
         is a highly selective alpha-2 agonist with sedative, sympatholytic, and analgesic properties that may be administered as an adjuvant for general anesthesia or for conscious sedation for awake craniotomy and other neurosurgical procedures [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Both animal and human studies have shown that
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         is a cerebral vasoconstrictor that causes a dose-dependent reduction in CBF [
         <a href="#rid79">
          79-83
         </a>
         ]. The other effects of this drug on cerebral physiology are less clear and may be species dependent. In dogs, dexmedetomidine has been consistently shown to have no effect on CMR; this, coupled with a reduction in CBF, could lead to cerebral ischemia. In humans, dexmedetomidine may reduce CMR along with CBF, similar to other IV anesthetics. A study in which healthy human volunteers received dexmedetomidine sedation reported parallel reductions in CMR and CBF, unchanged during hyperventilation [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The vasoconstrictive property of
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         may be of theoretical concern in patients at risk for regional cerebral ischemia or compromised flow metabolism coupling (eg, traumatic brain injury [TBI], subarachnoid hemorrhage, intracranial lesions). However, data regarding this issue are limited. A small, retrospective study of patients with acute neurologic injury related to vascular lesions reported no reduction in brain tissue PO
         <sub>
          2
         </sub>
         with dexmedetomidine administration during craniotomy [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8564163">
         <span class="h4">
          Neuromuscular blocking agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients are typically paralyzed during anesthesia for craniotomy unless neuromonitoring precludes the administration of NMBAs. If the anesthetic is lightened during less stimulating periods of surgery, maintenance of neuromuscular block can reduce the chance of coughing or movement.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe cough can result in straining, increased ICP, and brain herniation through the craniotomy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Movement while skull pins are in place can lead to slipping at the pin site, bleeding, and possible cervical spine injury.
        </p>
        <p>
        </p>
        <p>
         For patients with upper motor nerve lesions and weakness or paralysis, the twitch monitor used to guide NMBA dosing and reversal should be placed on the unaffected side. (See
         <a class="medical medical_review" href="/z/d/html/114324.html" rel="external">
          "Monitoring neuromuscular blockade", section on 'Paralyzed limb'
         </a>
         .)
        </p>
        <p>
         Neuromuscular monitoring should always be used to guide administration of NMBAs, preferably with a quantitative monitor. We maintain relatively deep neuromuscular block (ie, one to two twitches on train of four stimulation) until the head frame is released from the operating table. Cough and movement while the skull is still fixed in place can result in cervical spine injury. Importantly, required doses of NMBAs may be increased in patients who chronically take antiseizure drugs, whereas acute administration of antiseizure drugs (eg, for prophylaxis during surgery) may potentiate neuromuscular block [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H356126400">
         <span class="h3">
          Hemodynamic management
         </span>
        </p>
        <p class="headingAnchor" id="H3722767260">
         <span class="h4">
          Goal for intraoperative blood pressure
         </span>
         <span class="headingEndMark">
          —
         </span>
         MAP should be controlled during craniotomy to maintain acceptable CPP (ie, MAP - ICP, or MAP - central venous pressure [CVP] if CVP &gt; ICP). We suggest aiming for a CPP of 65 to 80 mmHg. Assuming a normal ICP (or CVP) range of 5 to 10 mmHg, MAP of 75 to 90 mmHg is a reasonable target range for an uncomplicated patient.
        </p>
        <p>
         With some individual variation, autoregulation of CBF typically occurs within a MAP range of 60 to 150 mmHg [
         <a href="#rid86">
          86
         </a>
         ]. Outside of this range, the brain is unable to compensate for changes in perfusion pressure, and the CBF increases or decreases passively with corresponding changes in pressure, resulting in the risk of ischemia at low pressures and edema or hemorrhage at high pressures. We aim for a MAP above the lower limit of autoregulation, with a margin for error.
        </p>
        <p>
         The following considerations should determine the goal BP during craniotomy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient factors
         </strong>
         – Patient comorbidities may require modification of the goal BP during craniotomy. Normal cerebral autoregulation may be disrupted in patients with ischemic stroke [
         <a href="#rid87">
          87
         </a>
         ], TBI [
         <a href="#rid88">
          88
         </a>
         ], diabetes [
         <a href="#rid89">
          89
         </a>
         ], and hypertension. A study of awake patients with drug-induced hypotension reported that the lower limit of cerebral autoregulation was increased in patients with chronic hypertension compared with normotensive controls (113 versus 73 mmHg) [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with hypertension, we usually aim for a MAP close to baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Reviewing cerebral imaging, estimating the patient's preoperative BP, and obtaining information about possible fluctuations in the neurologic examination that might be related to changes in BP preoperatively are warranted for decision making.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intracranial pathology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cerebral autoregulation might be blunted or abolished in certain conditions, either regionally (eg, brain tumors) [
         <a href="#rid91">
          91
         </a>
         ] or globally (eg, TBI) [
         <a href="#rid92">
          92,93
         </a>
         ]. In areas of intracranial pathology, CBF will be partially or entirely dependent on BP. In many patients with elevated ICP, MAP should be increased to maintain CPP. However, in patients with TBI, ICP should be reduced first, rather than increasing BP, as augmenting BP may worsen cerebral edema in these patients and further elevate ICP. This issue is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94283.html" rel="external">
          "Anesthesia for patients with acute traumatic brain injury", section on 'Goal intracranial pressure and cerebral perfusion pressure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There is no widely available real-time monitor for cerebral autoregulatory dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Occlusive disease of the cerebral arteries may lead to reliance on collateral arterial blood flow; higher CPP would be required to perfuse the ipsilateral brain. BP management during endovascular therapy for ischemic stroke is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/114425.html" rel="external">
          "Anesthesia for endovascular therapy for acute ischemic stroke in adults", section on 'Hemodynamic management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Procedure-related factors
         </strong>
         – Surgical maneuvers (eg, application of a temporary clip on a major cerebral artery) may require a higher CPP to assure collateral circulation [
         <a href="#rid94">
          94
         </a>
         ]. By contrast, a lower BP may be required during specific portions of intracranial vascular procedures.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2755766683">
         <span class="h4">
          Vasoactive drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vasoactive drugs are commonly administered during anesthesia for craniotomy to achieve BP goals. The effects of these drugs on cerebral physiology are complex and reflect the baseline BP, the status of autoregulatory mechanisms, the mechanism of the drug effect, and the magnitude of BP change:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vasopressors
         </strong>
         – Vasoconstrictors are often administered to counteract the vasodilation that is typically caused by anesthetic agents. Small boluses of short-acting agents are often administered during induction of anesthesia (eg,
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         5 to 10 mg IV,
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         40 to 80 mcg IV). An infusion of a vasopressor may be required during maintenance of anesthesia, especially during periods of reduced surgical stimulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Phenylephrine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          Phenylephrine
         </a>
         , a direct alpha-1 adrenergic agonist, is usually the first-choice agent in this setting. The effect of phenylephrine on CBF is controversial. Pure alpha agonists are thought to be systemic, but not cerebral, vasoconstrictors. Therefore, in most circumstances, when BP is increased with phenylephrine, CBF increases [
         <a href="#rid95">
          95-98
         </a>
         ]. However, several studies in anesthetized patients [
         <a href="#rid99">
          99,100
         </a>
         ], and others in awake volunteers [
         <a href="#rid101">
          101,102
         </a>
         ], have suggested that under at least some circumstances, phenylephrine may be associated with a decrease in cerebral oxygenation. Methodologic concerns have been raised over the use of near-infrared spectroscopy (NIRS) for these studies [
         <a href="#rid103">
          103
         </a>
         ], but the possibility of decreased cerebral perfusion with phenylephrine in patients at particular risk should be considered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other vasopressors
         </strong>
         – Effects of infusions of vasopressors may be different, even at the same BP. Two small studies found improved CBF with
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         infusion versus
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         [
         <a href="#rid104">
          104
         </a>
         ]. Ephedrine is not typically administered as an infusion, and further study is required before recommending ephedrine infusion rather than phenylephrine during craniotomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a randomized trial of patients with supratentorial brain tumors who were assessed with positron emission tomography (PET) after induction of anesthesia,
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         infusion was associated with improved CBF and regional cerebral oxygen saturation in the normal brain hemisphere but not in the diseased hemisphere, compared with
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         , at similar BPs [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In another randomized trial of 24 patients who underwent craniotomy for brain tumor and were assessed with magnetic resonance imaging (MRI) and NIRS after induction of anesthesia,
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         infusion improved CBF and tissue oxygenation in both cerebral hemispheres [
         <a href="#rid105">
          105
         </a>
         ]. By contrast,
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         infusion reduced capillary transit time heterogeneity (a measure of cerebral oxygenation) in the hemisphere without tumor. Both groups had similar mean arterial BPs.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Other vasopressors may be indicated, depending on the patient's cardiac function and other comorbidities. A beta-1 adrenergic receptor agonist (eg,
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         , an inotrope) or an agent with both alpha and beta agonist properties (eg,
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         ) may be required. Low-dose
         <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">
          vasopressin
         </a>
         (eg, 0.01 to 0.04 units per minute) may be useful as a supplementary vasopressor for hypotension refractory to other treatment. Vasopressin at higher doses is usually avoided because it can cause cerebral vasoconstriction [
         <a href="#rid106">
          106
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">
          "Use of vasopressors and inotropes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Similar to
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         , a study of awake volunteers reported a reduction in cerebral oxygenation when
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         was administered [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vasodilators
         </strong>
         – Vasodilators or beta blockers may be required during maintenance of and emergence from anesthesia. (See
         <a class="local">
          'Emergence from anesthesia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Vasodilators (ie,
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         ,
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         , and calcium channel blockers) dilate the cerebral circulation and can increase CBF if adequate MAP is maintained. Therefore, vasodilators should be used with caution in patients with increased ICP, as these drugs may increase CBV and exacerbate intracranial hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Beta blockers
         </strong>
         – Beta blockers either reduce or have no effect on CBF and CMR [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2576157126">
         <span class="h4">
          Our approach to hemodynamic management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the maintenance of adequate mean BP is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optimize intravascular volume. (See
         <a class="local">
          'Fluid management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Titrate anesthetic agents to match the level of surgical stimulus in order to minimize hypotensive anesthetic effects and hypertensive responses to stimulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment of hypotension, treat initially with
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         5 to 10 mg IV, particularly if hypotension is likely temporary, as occurs before an expected surgical stimulus (eg, incision).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thereafter, administer
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         by infusion at the lowest dose necessary to achieve adequate CPP, titrated to effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treat hypertension by deepening the anesthetic and, if necessary, by administering titrated boluses of short-acting vasodilators (eg,
         <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">
          labetalol
         </a>
         5 to 10 mg IV,
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         20 to 50 mg bolus) or, if necessary, by vasodilator infusion (eg,
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         10 to 400 mcg/minute IV, or
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          nicardipine
         </a>
         2.5 to 15 mg/hour).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H356126413">
         <span class="h3">
          Antiseizure drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seizure can occur in 15 to 20 percent of patients without history of epilepsy following a nontraumatic supratentorial craniotomy. We administer a single dose of
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         prior to incision for supratentorial craniotomy. Levetiracetam,
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         , and
         <a class="drug drug_general" data-topicid="8480" href="/z/d/drug information/8480.html" rel="external">
          fosphenytoin
         </a>
         are equally effective for seizure prophylaxis. We administer levetiracetam because in contrast with the other two drugs, it is not associated with hypotension during administration, has more reliable pharmacokinetics, and does not require serum monitoring. Also, unlike phenytoin, there is no concern over tissue injury with extravasation of levetiracetam.
        </p>
        <p>
         Options for antiseizure drugs in this setting include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Levetiracetam
         </strong>
         – 500 to 1000 mg IV, up to 3000 mg IV as indicated
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fosphenytoin
         </strong>
         – 10 to 20 mg
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         equivalents (PE)/kg over 30 minutes, maximum rate 150 mg PE/minute
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phenytoin
         </strong>
         – 15 mg/kg IV, ≤50 mg/minute
         <strong>
         </strong>
         to avoid hypotension and bradycardia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          Phenytoin
         </a>
         is rarely administered where
         <a class="drug drug_general" data-topicid="8480" href="/z/d/drug information/8480.html" rel="external">
          fosphenytoin
         </a>
         is available. Extravasation during administration of IV phenytoin may cause severe tissue necrosis, and inadvertent intra-arterial administration of phenytoin has been associated with gangrene.
        </p>
        <p>
        </p>
        <p>
         Patients who are taking antiseizure medications preoperatively should be maintained on their regular doses throughout the perioperative setting to avoid seizures.
        </p>
        <p class="headingAnchor" id="H8564169">
         <span class="h3">
          Fluid management
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest maintaining normovolemia to achieve adequate cerebral perfusion and to avoid cerebral edema. IV fluid should be administered at a rate and volume that achieves even fluid balance. The following general principles apply:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of crystalloid solution
         </strong>
         – Isotonic (eg, plasmalyte), slightly hypotonic (eg, Ringer's lactate), or slightly hypertonic (eg, 0.9 percent sodium chloride [NaCl]) crystalloid solutions can be administered as maintenance fluid during craniotomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hypotonic fluid
         </strong>
         – Hypotonic fluids can increase brain interstitial fluid even in the healthy state [
         <a href="#rid109">
          109,110
         </a>
         ]. When used in moderation, this effect is likely not clinically significant.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Isotonic fluid
         </strong>
         – Isotonic crystalloid solutions do not increase the interstitial fluid content of the brain with an intact blood-brain barrier.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hypertonic fluid
         </strong>
         – Hypertonic solutions decrease the interstitial fluid content of the brain with an intact blood-brain barrier, pulling water across the cerebral capillary endothelium down its osmotic gradient. Hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         (HTS) can increase the volume of the brain with impaired blood-brain barrier function [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Large volumes of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         (0.9 percent NaCl) can cause hyperchloremic acidosis [
         <a href="#rid112">
          112
         </a>
         ]. As an alternative, plasmalyte, or Ringer's lactate alternating with saline, can be used to avoid hyperchloremic acidosis. (See
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Colloid solutions
         </strong>
         – Colloid administration during craniotomy is controversial, especially for patients with TBI (see
         <a class="medical medical_review" href="/z/d/html/94283.html" rel="external">
          "Anesthesia for patients with acute traumatic brain injury", section on 'Intraoperative fluid management'
         </a>
         ). A post hoc analysis of resuscitation with albumin compared with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         in patients with severe TBI reported worse long-term outcome with albumin [
         <a href="#rid113">
          113
         </a>
         ]. However, this finding may not apply to intraoperative fluid management with cerebral edema from other causes. In a hypovolemic and hypotensive patient, 5 or 25 percent albumin can be used to restore intravascular volume status quickly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Starch solutions should be avoided for craniotomy because they can interfere with platelet function and the factor VII clotting complex [
         <a href="#rid114">
          114
         </a>
         ] and could result in bleeding. (See
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management", section on 'Hydroxyethyl starches'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluid balance
         </strong>
         – We aim for an even fluid balance during craniotomy. Positive fluid balance can create or worsen cerebral edema [
         <a href="#rid109">
          109
         </a>
         ], while hypovolemia may reduce CPP.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Urine output can be large when
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         and diuretics are administered for brain relaxation. In this setting, we match urine output with fluid administration, modified as required to replace blood loss, and we use 0.9 percent
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management", section on 'Monitoring intravascular volume status'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H336791146">
         <span class="h3">
          Ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal partial pressure of CO
         <sub>
          2
         </sub>
         (PaCO
         <sub>
          2
         </sub>
         ) should be discussed with the surgeon preoperatively. Hyperventilation should be used only when indicated. Hyperventilation and the resulting reduction in CBF may be required to reduce ICP or to improve surgical exposure by relaxing the brain. (See
         <a class="local">
          'Planned brain relaxation'
         </a>
         below.)
        </p>
        <p>
         General considerations include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypercarbia should always be avoided during craniotomy. Elevations in PaCO
         <sub>
          2
         </sub>
         result in increased CBF and may increase ICP. Unless hyperventilation is required, we maintain PaCO
         <sub>
          2
         </sub>
         at 35 to 38 mmHg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Therapeutic hyperventilation should be guided by blood gases rather than by end-tidal CO
         <sub>
          2
         </sub>
         (ETCO
         <sub>
          2
         </sub>
         ). While ETCO
         <sub>
          2
         </sub>
         generally correlates well with PaCO
         <sub>
          2
         </sub>
         , a number of factors (eg, age, lung disease, surgical positioning) can result in significant discrepancy [
         <a href="#rid115">
          115,116
         </a>
         ]. In our clinical experience, PaCO
         <sub>
          2
         </sub>
         is commonly 8 to 10 mmHg higher than ETCO
         <sub>
          2
         </sub>
         in patients with chronic obstructive pulmonary disease (COPD), though this difference is variable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The vasoconstriction that accompanies hyperventilation may result in ischemia, particularly for at-risk brain tissue (eg, after TBI, after subarachnoid hemorrhage, or under surgical retractors during craniotomy). Hyperventilation to a PaCO
         <sub>
          2
         </sub>
         of 25 to 30 mmHg can improve surgical conditions during supratentorial craniotomy [
         <a href="#rid117">
          117
         </a>
         ]. However, multiple human and animal studies using a variety of methodologies have reported evidence of brain ischemia in injured brains with hyperventilation to a PaCO
         <sub>
          2
         </sub>
         of 25 to 30 mmHg [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As part of a multimodal approach to brain relaxation for surgical exposure, we hyperventilate as briefly as possible to achieve a PaCO
         <sub>
          2
         </sub>
         of 30 to 35 mmHg. Ventilation should be returned to normal gradually to avoid rebound cerebral vasodilation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hyperventilation for acute cerebral edema is discussed below. (See
         <a class="local">
          'Intraoperative cerebral edema'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8564183">
         <span class="h3">
          Brain relaxation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Brain relaxation, or brain shrinkage, may be part of the surgical plan or may be required in response to unexpected brain swelling or tightness during the procedure.
        </p>
        <p>
        </p>
        <p>
         Brain relaxation or shrinkage may be required to improve surgical exposure and to avoid ischemia related to pressure from retractors placed during surgery. Techniques for this purpose include administration of diuretics to reduce intravascular volume,
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         or HTS for osmotherapy, glucocorticoids to reduce swelling, hyperventilation for vasoconstriction, and elevation of the patient's head to facilitate venous drainage. For some procedures, a lumbar or ventricular CSF drain is placed preoperatively to reduce brain bulk.
        </p>
        <p>
         Osmotherapy works by creating an osmotic gradient that draws water out of brain tissue to reduce brain bulk. Effective osmotherapy with
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         or HTS requires an intact blood-brain barrier; areas of brain with a disrupted blood-brain barrier may swell more with osmotherapy [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H549870077">
         <span class="h4">
          Planned brain relaxation
         </span>
         <span class="headingEndMark">
          —
         </span>
         When brain relaxation is planned as part of the procedure, in consultation with the surgeon, we use the following regimen after induction of anesthesia:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          Furosemide
         </a>
         10 to 20 mg IV
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         10 mg IV
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osmotherapy with
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         0.5 to 1 g/kg IV administered slowly, over 10 to 15 minutes to avoid hypotension, or 3 percent HTS 3 to 5 mL/kg [
         <a href="#rid119">
          119
         </a>
         ] (see
         <a class="local">
          'Intraoperative cerebral edema'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperventilation to ETCO
         <sub>
          2
         </sub>
         27 to 32 mmHg (aiming for PaCO
         <sub>
          2
         </sub>
         of 30 to 35 mmHg) (see
         <a class="local">
          'Ventilation'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H549870084">
         <span class="h4">
          Intraoperative cerebral edema
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the surgeon encounters cerebral edema (ie, the "tight brain"), management requires a quick review of the physiologic principles of ICP dynamics and optimization. We use the following checklist to manage cerebral edema:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Optimize cerebral venous drainage
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Elevate the head – This should be the first maneuver used to improve venous drainage from the brain. If possible, adjust the head rotation and flexion.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduce intrathoracic pressure – Positive intrathoracic pressure impedes venous return to the right heart, including from the brain. If oxygenation permits, reduce or discontinue positive end-expiratory pressure (PEEP) and adjust the ventilator settings to decrease mean airway pressure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reverse any cerebral vasodilation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Optimize ventilation – Increase in minute ventilation may reduce cerebral vasodilation, depending on the starting ETCO
         <sub>
          2
         </sub>
         and PaCO
         <sub>
          2
         </sub>
         . Send an arterial blood gas to guide therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Convert to IV anesthesia – Discontinue volatile anesthetics and N
         <sub>
          2
         </sub>
         O.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treat elevated CMR – Maintain normothermia and adequate depth of anesthesia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drain CSF if possible
         </strong>
         – If an external ventricular drain (EVD) or lumbar drain is in place, evacuation of CSF can rapidly reduce ICP. CSF should be drained in increments (eg, 5 to 10 mL at a time) with ongoing assessment of brain conditions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Start osmotherapy
         </strong>
         – If the steps above are ineffective, osmotherapy is indicated. For osmotherapy to treat intraoperative cerebral edema, we administer 0.5 to 1 g/kg of
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         , 3 to 5 mL/kg of 3 percent NaCl, or 0.4 mL/kg of 23.4 percent NaCl over 15 to 20 minutes. For emergent therapy (eg, active brainstem herniation), we administer 23.4 percent NaCl, 30 mL over ≤3 minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          Mannitol
         </a>
         (usually 20 percent solution) and various concentrations (3, 7.5, and 23.4 percent) of HTS have comparable efficacy in equiosmolar doses [
         <a href="#rid120">
          120
         </a>
         ]; 20 percent mannitol and 3 percent NaCl are roughly equi-osmolar. The following considerations apply during osmotherapy [
         <a href="#rid121">
          121,122
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mannitol
         </strong>
         – Twenty percent
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         can be administered via a peripheral IV and should be infused over 15 to 20 minutes to avoid hypotension. Mannitol causes an initial increase in intravascular volume followed by osmotic diuresis and net negative fluid balance. Mannitol should be avoided in patients who may not tolerate the initial increase in intravascular volume (eg, patients with congestive heart failure) or who cannot eliminate mannitol (eg, patients with renal dysfunction).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          HTS
         </strong>
         – Three percent NaCl can be administered via a peripheral IV, while more concentrated solutions (ie, 7.5 and 23.4 percent) must be administered through a CVC; except for emergent situations, HTS should be infused over 15 to 20 minutes. HTS causes a sustained increase in plasma volume. Concerns related to HTS therapy include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Rapid administration of HTS can result in hypervolemia and hypertension due to rapid expansion of blood volume; this is rarely of clinical concern in the operating room (OR).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Rapid administration of HTS can cause acute elevation of serum sodium. As an example, administration of approximately 5 mEq/kg of sodium (approximately 45 mL of 23.4 percent NaCl) over two minutes can increase plasma sodium from 140 to 152 mEq/L. While osmotic demyelination syndrome (ODS) has occurred with rapid elevation in patients with severe hyponatremia, there are no reports of ODS occurring in the setting of osmotherapy for brain relaxation in normonatremic patients. (See
         <a class="medical medical_review" href="/z/d/html/2317.html" rel="external">
          "Osmotic demyelination syndrome (ODS) and overly rapid correction of hyponatremia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Rapid administration of concentrated HTS (ie, 30 mL of 23.4 percent NaCl over less than one minute) can cause osmotic disruption of the blood-brain barrier, which can result in seizures, cerebral edema, and intracranial hypertension. If seizure occurs and if the dura is open, first-line treatment should be irrigation of the brain with iced
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . If necessary, further treatment includes
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         10 to 20 mg IV or
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         1 to 2 mg IV to terminate the seizure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treat refractory intracranial hypertension
         </strong>
         –
         <strong>
         </strong>
         High-dose barbiturate therapy (eg,
         <a class="drug drug_general" data-topicid="9754" href="/z/d/drug information/9754.html" rel="external">
          pentobarbital
         </a>
         5 to 20 mg/kg IV bolus, followed by 1 to 4 mg/kg per hour, titrated to EEG burst suppression) may be used to control elevated ICP refractory to maximum standard medical treatment. It should be noted that pentobarbital, even after administration for a few hours at this dose range, will have a very long context-sensitive half-life. Vasopressor therapy may be required to maintain adequate CPP if high-dose barbiturate causes hypotension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternatively,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         can be used to help control ICP, but caution is required as high-dose propofol is associated with hypotension and propofol infusion syndrome. (See
         <a class="medical medical_review" href="/z/d/html/4826.html" rel="external">
          "Management of acute moderate and severe traumatic brain injury", section on 'Sedation and analgesia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H258395592">
         <span class="h3">
          Brain protection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of temperature and glucose is important for patients with brain injury and ischemia (eg, during aneurysm clipping). In addition, in these settings, medications are often administered for neuroprotection (eg, barbiturates,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ). Neuroprotection during craniotomy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94284.html" rel="external">
          "Anesthesia for intracranial neurovascular procedures in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94283.html" rel="external">
          "Anesthesia for patients with acute traumatic brain injury", section on 'Neuroprotection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8564245">
         <span class="h3">
          Glycemic control
         </span>
         <span class="headingEndMark">
          —
         </span>
         We manage glucose and insulin administration (IV bolus or infusion of
         <a class="drug drug_general" data-topicid="9030" href="/z/d/drug information/9030.html" rel="external">
          regular insulin
         </a>
         ) to achieve blood glucose of 110 to 150 mg/dL and treat values above 180 mg/dL. Neither the glucose level above which neuronal damage occurs nor an ideal target plasma glucose concentration has been established, but tight glucose control (ie, target blood glucose of 80 to 110 mg/dL) is associated with increased risk of hypoglycemia. (See
         <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">
          "Glycemic control in critically ill adult and pediatric patients"
         </a>
         .)
        </p>
        <p>
         Hypoglycemia causes and exacerbates neuronal damage and should be avoided during craniotomy [
         <a href="#rid123">
          123
         </a>
         ]. However, hyperglycemia is associated with increased morbidity and mortality after TBI [
         <a href="#rid124">
          124-126
         </a>
         ] and decreased survival after brain tumor resection [
         <a href="#rid127">
          127,128
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94283.html" rel="external">
          "Anesthesia for patients with acute traumatic brain injury", section on 'Glucose management'
         </a>
         .)
        </p>
        <p>
         Intraoperative hyperglycemia has also been shown to be associated with increased risk of postoperative infection [
         <a href="#rid129">
          129,130
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8564274">
         <span class="h2">
          Emergence from anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients are awoken and extubated in the OR after craniotomy.
        </p>
        <p class="headingAnchor" id="H758802342">
         <span class="h3">
          Management of emergence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Important aspects of emergence after craniotomy include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Readiness for extubation
         </strong>
         – Extubation may be delayed for patients who undergo infratentorial surgery if there are concerns for lower cranial nerve dysfunction that might impact airway reflexes, and for patients who undergo long procedures in the prone position [
         <a href="#rid131">
          131-133
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/114423.html" rel="external">
          "Anesthesia for posterior fossa craniotomy", section on 'Emergence and extubation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94224.html" rel="external">
          "Extubation following anesthesia", section on 'Higher-risk extubation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minimal residual anesthesia
         </strong>
         – Ideally, the patient should be awake enough for an adequate neurologic examination (eg, responding to commands, moving all extremities on command, adequate vision assessment) before leaving the OR.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pain control during emergence
         </strong>
         – In contrast with other surgical procedures, opioids should not be administered at a dose that is expected to prevent anticipated pain, but rather titrated as needed following extubation and neurologic examination. Liberal opioid dosing based on anticipated pain or guided by hemodynamic endpoints (eg, to keep systolic BP below 160 mmHg) often results in somnolence, a delay in a satisfactory neurologic examination, and occasionally unnecessary head imaging.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients without preoperative altered mental status and for those who were taking opioids preoperatively, we usually administer
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         3 to 5 mg IV or
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         0.5 mg IV 30 minutes prior to emergence, and titrate further opioid postoperatively after neurologic examination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who receive scalp blocks may awaken from anesthesia with little or no pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic management
         </strong>
         – Following a routine tumor resection for a patient without chronic hypertension or with controlled chronic hypertension, we aim to maintain a systolic BP of &lt;160 mmHg, as systolic pressures &gt;160 mmHg are associated with increased risk of postoperative intracranial hemorrhage [
         <a href="#rid134">
          134,135
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hypertension is common on emergence from anesthesia for craniotomy and should be treated quickly. In addition to an association with intracranial hemorrhage [
         <a href="#rid134">
          134
         </a>
         ], hypertension can worsen cerebral edema in those areas where the blood-brain barrier is disrupted. Treatment should be titrated to avoid hypotension, cerebral hypoperfusion, and enlargement of an area of cerebral ischemia [
         <a href="#rid136">
          136
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Medications commonly administered to control hypertension on emergence after craniotomy include
         <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">
          labetalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          nicardipine
         </a>
         . We typically start with IV labetalol because it is easy to dose and, compared with esmolol, has a duration of action long enough to permit safe transport to the postanesthesia care unit (PACU) or intensive care unit (ICU). If labetalol is contraindicated or not effective at doses up to 300 mg per hour, nicardipine infusion would be warranted and provides ongoing hemodynamic control during transfer of care.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A prospective study of preemptive BP control in 42 patients who underwent craniotomy found that when added to
         <a class="drug drug_general" data-topicid="17094" href="/z/d/drug information/17094.html" rel="external">
          enalaprilat
         </a>
         ,
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          nicardipine
         </a>
         (2 mg boluses IV) was as effective as
         <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">
          labetalol
         </a>
         (5 mg boluses IV) at controlling postoperative BP [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Perioperative use of these medications is discussed separately  (
         <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/141346.html" rel="external">
          "Intraoperative use of vasoactive agents", section on 'Antihypertensive agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The duration and severity of postoperative hypertension vary. Some patients require only a few intermittent boluses of antihypertensive medication, while others may need a continuous infusion to control BP. Preexisting and uncontrolled hypertension may predict the need for more intensive and prolonged treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Once the patient is transferred to the PACU or ICU, it is important to communicate the BP goals and doses of medication administered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ICP control
         </strong>
         – During emergence, every effort should be made to avoid coughing, straining, retching, and vomiting, all of which can increase CVP and ICP. Prophylactic antiemetics should be administered routinely, and airway suctioning should be performed before the depth of anesthesia is lightened.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         During emergence, ventilation should be assisted until the patient maintains adequate minute ventilation. Hypoventilation on emergence can result in increased PaCO
         <sub>
          2
         </sub>
         and can cause cerebral vasodilation and increased ICP.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8564316">
         <span class="h3">
          Delayed emergence
         </span>
         <span class="headingEndMark">
          —
         </span>
         When the patient is slow to emerge from anesthesia, the cause may be related to surgical, anesthetic, preexisting, or physiologic factors. If the patient has a significant preoperative neurologic deficit, emergence may be delayed and extubation may need to be deferred. In patients with preoperative deficits and in whom there is a high likelihood that the surgical procedure may improve the patient's mental status (eg, evacuation of a large epidural hematoma), neurologic examination may be attempted and extubation considered.
        </p>
        <p>
         As some potential causes require emergent action, assessment of the patient who fails to emerge from anesthesia should include the surgeon and should proceed in a systematic fashion. Causes, evaluation, and management of delayed emergence are discussed separately  (
         <a class="graphic graphic_table graphicRef106223" href="/z/d/graphic/106223.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">
          "Delayed emergence and emergence delirium in adults", section on 'Delayed emergence'
         </a>
         .)
        </p>
        <p>
         After craniotomy, cerebral edema, intracerebral hematoma, tension pneumocephalus, and ischemia (total occlusion of an artery or hypoperfusion) are potential surgical causes for a delayed emergence. Pupils should be examined along with response to pain and reflexes.
        </p>
        <p>
         When no cause for delayed emergence can be identified, an emergent CT scan should be performed to assess for intracranial hemorrhage, brain edema, pneumocephalus, or other pathology.
        </p>
        <p class="headingAnchor" id="H2653637192">
         <span class="h3">
          Differential emergence or awakening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transient focal neurologic deficits can occur following sedation or general anesthesia in patients with a prior history of a neurologic deficit related to stroke, brain tumor, and carotid disease. In the context of anesthesia, this phenomenon has been called differential awakening; patients typically exhibit a focal motor deficit immediately upon emergence that improves over 30 minutes to several hours. The mechanism remains to be elucidated, but the time course suggests a pharmacologic cause.
        </p>
        <p>
         Transient focal neurologic deficits have been elicited with administration of both sedatives and opioids to patients with a history of neurologic deficits [
         <a href="#rid138">
          138-141
         </a>
         ], and in patients with brain mass lesions without known deficits [
         <a href="#rid142">
          142,143
         </a>
         ]. Reversal of opioid-induced deficits with
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         and of midazolam-induced deficits with
         <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">
          flumazenil
         </a>
         [
         <a href="#rid143">
          143
         </a>
         ] have been reported.
        </p>
        <p>
         When a focal neurologic deficit is evident on emergence from anesthesia, multidisciplinary evaluation should be performed, with differential emergence included among potential etiologies.
        </p>
        <p class="headingAnchor" id="H8564348">
         <span class="h1">
          POSTOPERATIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although debated, even an uneventful craniotomy remains an indication for admission to the intensive care unit (ICU) [
         <a href="#rid144">
          144
         </a>
         ]. The primary indication for intensive care is to allow serial (usually hourly) neurologic examinations and rapid response to abnormalities. In addition, postoperative intensive care allows continuous blood pressure (BP) monitoring and control, increased intracranial pressure (ICP) monitoring when required, and treatment of pain and postoperative nausea and vomiting (PONV).
        </p>
        <p>
         Some institutions have created postoperative pathways for transfer of selected patients from the operating room (OR) to the postanesthesia care unit (PACU), and then to a stepdown unit rather than the ICU. In a single-institution observational study of 324 patients who underwent neurosurgical procedures, 94 of whom went through a protocol that bypassed the ICU, length of hospital stay and costs were less in patients who bypassed the ICU, and there were no significant complications or adverse outcomes in those patients [
         <a href="#rid145">
          145
         </a>
         ]. Patient eligibility criteria for bypassing the ICU included age ≤65 years; no comorbidity requiring ICU-level care; if craniotomy for tumor, supratentorial and tumor &lt;3 cm; no intraoperative adverse events; duration of surgery &lt;5 hours; estimated blood loss &lt;50 mL; and routine extubation.
        </p>
        <p>
         Patients who undergo awake craniotomy are commonly sent to the PACU and then an inpatient floor, rather than the ICU. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94288.html" rel="external">
          "Anesthesia for awake craniotomy", section on 'Postoperative care'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H144868850">
         <span class="h2">
          Postoperative pain control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Up to 75 percent of patients experience moderate to severe pain in the first few days after craniotomy [
         <a href="#rid146">
          146-148
         </a>
         ]. Acute pain is often more severe after infratentorial compared with other types of craniotomy [
         <a href="#rid148">
          148
         </a>
         ], possibly due to retraction and incision of muscles in the region. A significant portion of patients continue to have headache for months or years after craniotomy [
         <a href="#rid149">
          149,150
         </a>
         ]. Although severe acute postoperative pain is associated with increased risk of persistent pain, it is unclear whether effective control of acute pain reduces the incidence of chronic pain.
        </p>
        <p>
         Similar to other types of surgery, multimodal opioid-sparing analgesic strategies are increasingly used for craniotomy. Pain control may include local anesthetic infiltration of the incision, scalp blocks,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , and opioids. Nonsteroidal anti-inflammatory drugs (NSAIDs) are avoided due to potential for bleeding.
        </p>
        <p>
         Scalp blocks may be used for early postoperative pain control for craniotomy and are part of some enhanced recovery after surgery (ERAS) protocols for craniotomy [
         <a href="#rid151">
          151
         </a>
         ]. Scalp blocks may provide some analgesic benefits and can be quickly performed before anesthesia, after induction, or at the end of the case prior to emergence. The author uses scalp blocks for awake craniotomy, but not routinely for craniotomy with general anesthesia.
        </p>
        <p>
         The evidence in support of scalp blocks is inconsistent with respect to pain scores and postoperative analgesic use.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2019 meta-analysis of randomized trials that evaluated scalp block for craniotomy, scalp block produced a modest decrease in postoperative pain scores at 0 to 6 hours (10 studies, 44 patients) and 12 hours (8 studies, 294 patients) postoperatively, mean difference 0.98 and 0.95 on a 0 to 10 scale, respectively [
         <a href="#rid152">
          152
         </a>
         ]. Scalp blocks reduced postoperative opioid requirement (7 studies, 324 patients), 149 versus 165
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         milligram equivalents. For this outcome, there was very high statistical heterogeneity. The quality of evidence was low or very low for all outcomes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2020 randomized trial of 89 patients who underwent supratentorial craniotomy, bilateral scalp blocks did not reduce postoperative pain scores or opioid consumption during the first 24 hours after surgery [
         <a href="#rid153">
          153
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A single-center prospective observational study evaluated postoperative pain outcomes in 134 patients who underwent supratentorial craniotomy with multimodal analgesia , 46 of whom also received bilateral scalp blocks [
         <a href="#rid154">
          154
         </a>
         ]. Multimodal analgesia consisted of intraoperative
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          tramadol
         </a>
         and
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , and postoperative acetaminophen and as-needed opioids. Scalp block was associated with reduced need for postoperative rescue analgesia in the first 48 hours (39 versus 65 percent of patients). There was no difference in postoperative pain scores in patients who received scalp blocks.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8564494">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preoperative planning
         </strong>
         –
         <strong>
         </strong>
         The anesthesiologist and surgeon should discuss preexisting increased intracranial pressure (ICP), positioning for surgery, the risk of venous air embolism (VAE), goals for blood pressure (BP) and ventilation (goal partial pressure of carbon dioxide [PaCO
         <sub>
          2
         </sub>
         ]), and whether neurophysiologic monitoring will be used. (See
         <a class="local">
          'General concerns'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of anesthetic technique
         </strong>
         –
         <strong>
         </strong>
         General endotracheal anesthesia is the preferred technique, though for specific indications, the craniotomy can be performed awake. (See
         <a class="local">
          'Anesthetic management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of anesthetic medications
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Total intravenous versus inhalation anesthesia
         </strong>
         –
         <strong>
         </strong>
         The optimal anesthetic regimen for elective craniotomy is controversial. In many cases, we use a balanced anesthetic including low doses of a potent inhalation anesthetic (ie,
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          isoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">
          desflurane
         </a>
         , and halothane), with or without
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O), and opioids. For patients with increased ICP, we suggest using a predominantly intravenous (IV) technique (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Maintenance of anesthesia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Effects on cerebral physiology
         </strong>
         –
         <strong>
         </strong>
         Anesthetics have a variety of effects on cerebral physiology  (
         <a class="graphic graphic_table graphicRef105673" href="/z/d/graphic/105673.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         IV induction agents – With the exception of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , IV induction agents (ie,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         , barbiturates,
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         ) cause reductions in both cerebral metabolic rate (CMR) and cerebral blood flow (CBF), resulting in no change or a decrease in ICP, while responsiveness to carbon dioxide (CO
         <sub>
          2
         </sub>
         ) is maintained. (See
         <a class="local">
          'Choice of induction agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Volatile anesthetics –
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          Isoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">
          desflurane
         </a>
         , and halothane are dose-dependent cerebral vasodilators. While they reduce CMR, they can blunt cerebral autoregulation by uncoupling CBF and metabolism, and they can increase CBF and ICP. Below 1 minimum alveolar concentration (MAC), there is a modest decrease in CBF. Above 1 MAC, CBF increases. Responsiveness to CO
         <sub>
          2
         </sub>
         is maintained. (See
         <a class="local">
          'Potent inhalation agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          Nitrous oxide
         </a>
         – N
         <sub>
          2
         </sub>
         O can increase CBF, CMR, and ICP, with preserved CO
         <sub>
          2
         </sub>
         responsiveness. The magnitude of changes in cerebral physiology with N
         <sub>
          2
         </sub>
         O is affected by the administration of other anesthetic drugs and by ventilation. (See
         <a class="local">
          'Nitrous oxide'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Propofol infusion –
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         infusion causes reduction in CMR, CBF, and ICP, while CO
         <sub>
          2
         </sub>
         responsiveness is maintained. (See
         <a class="local">
          'Intravenous anesthesia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Opioids – When administered with controlled ventilation, opioids have minimal effects on cerebral physiology. (See
         <a class="local">
          'Intravenous anesthesia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positioning
         </strong>
         –
         <strong>
         </strong>
         Positioning for craniotomy requires meticulous attention to detail to avoid nerve injury, skin pressure injuries, ocular injury, and airway compromise. Supine, prone, lateral, or sitting positions may be used. The sitting position is associated with a higher risk of VAE, hypotension, and pneumocephalus and is relatively contraindicated in those with a potential right-to-left intracardiac shunt. (See
         <a class="local">
          'Positioning'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood pressure goal
         </strong>
         –
         <strong>
         </strong>
         BP should be controlled during craniotomy to maintain adequate cerebral perfusion pressure (CPP). We suggest aiming for a CPP of 65 to 80 mmHg (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients without an ICP monitor, this translates to a mean arterial pressure (MAP) goal of 75 to 90 mmHg for an uncomplicated patient. For patients with an ICP monitor in place, the goal BP is determined by the existing ICP, using the formula CPP = MAP - ICP. For patients with hypertension, we aim for MAP close to baseline. (See
         <a class="local">
          'Hemodynamic management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluid management
         </strong>
         –
         <strong>
         </strong>
         We suggest administering IV fluid at a rate and volume that achieves even fluid balance to achieve adequate cerebral perfusion and to avoid cerebral edema (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients who receive
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         and/or diuretics for brain relaxation, we match urine output with IV crystalloid. We use 0.9 percent
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . (See
         <a class="local">
          'Fluid management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ventilation
         </strong>
         –
         <strong>
         </strong>
         Hypercarbia should always be avoided during craniotomy. Hyperventilation reduces CBF and may be required to reduce ICP or to improve surgical exposure by relaxing the brain. Hyperventilation should not be used routinely, as the vasoconstriction that accompanies hyperventilation may result in brain ischemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         When indicated, hyperventilation should be guided by blood gases rather than by end-tidal CO
         <sub>
          2
         </sub>
         (ETCO
         <sub>
          2
         </sub>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         When hyperventilation is used as part of multimodal approach to brain relaxation for surgical exposure, we suggest hyperventilating as briefly as possible to achieve a PaCO
         <sub>
          2
         </sub>
         of 30 to 35 mmHg (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Ventilation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brain relaxation
         </strong>
         –
         <strong>
         </strong>
         Brain relaxation may be part of the surgical plan, or it may be required in response to unexpected brain swelling. Planned brain relaxation usually includes administration of diuretic, glucocorticoid, osmotherapy with
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         or hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         (HTS), and hyperventilation. (See
         <a class="local">
          'Planned brain relaxation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management of intraoperative cerebral edema is described above. (See
         <a class="local">
          'Intraoperative cerebral edema'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Emergence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Emergence from anesthesia for craniotomy should be rapid and smooth to allow a postoperative neurologic examination.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Opioids should be titrated as needed for pain after emergence.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypertension is common on emergence and should be treated rapidly to avoid intracranial hemorrhage. (See
         <a class="local">
          'Emergence from anesthesia'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gupta PK, Gupta H, Sundaram A, et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. Circulation 2011; 124:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta H, Gupta PK, Fang X, et al. Development and validation of a risk calculator predicting postoperative respiratory failure. Chest 2011; 140:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costello TG, Cormack JR. Clonidine premedication decreases hemodynamic responses to pin head-holder application during craniotomy. Anesth Analg 1998; 86:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uyar AS, Yagmurdur H, Fidan Y, et al. Dexmedetomidine attenuates the hemodynamic and neuroendocrinal responses to skull-pin head-holder application during craniotomy. J Neurosurg Anesthesiol 2008; 20:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hans P, Brichant JF, Dewandre PY, et al. Effects of two calculated plasma sufentanil concentrations on the hemodynamic and bispectral index responses to Mayfield head holder application. J Neurosurg Anesthesiol 1999; 11:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger M, Philips-Bute B, Guercio J, et al. A novel application for bolus remifentanil: blunting the hemodynamic response to Mayfield skull clamp placement. Curr Med Res Opin 2014; 30:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsaousi GG, Logan SW, Bilotta F. Postoperative Pain Control Following Craniotomy: A Systematic Review of Recent Clinical Literature. Pain Pract 2017; 17:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guilfoyle MR, Helmy A, Duane D, Hutchinson PJ. Regional scalp block for postcraniotomy analgesia: a systematic review and meta-analysis. Anesth Analg 2013; 116:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carella M, Tran G, Bonhomme VL, Franssen C. Influence of Levobupivacaine Regional Scalp Block on Hemodynamic Stability, Intra- and Postoperative Opioid Consumption in Supratentorial Craniotomies: A Randomized Controlled Trial. Anesth Analg 2021; 132:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandesteene A, Trempont V, Engelman E, et al. Effect of propofol on cerebral blood flow and metabolism in man. Anaesthesia 1988; 43 Suppl:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petersen KD, Landsfeldt U, Cold GE, et al. Intracranial pressure and cerebral hemodynamic in patients with cerebral tumors: a randomized prospective study of patients subjected to craniotomy in propofol-fentanyl, isoflurane-fentanyl, or sevoflurane-fentanyl anesthesia. Anesthesiology 2003; 98:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox J, Gelb AW, Enns J, et al. The responsiveness of cerebral blood flow to changes in arterial carbon dioxide is maintained during propofol-nitrous oxide anesthesia in humans. Anesthesiology 1992; 77:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogura K, Takayasu M, Dacey RG Jr. Differential effects of pentobarbital on intracerebral arterioles and venules of rats in vitro. Neurosurgery 1991; 28:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michenfelder JD. The interdependency of cerebral functional and metabolic effects following massive doses of thiopental in the dog. Anesthesiology 1974; 41:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Astrup J, Rosenørn J, Cold GE, et al. Minimum cerebral blood flow and metabolism during craniotomy. Effect of thiopental loading. Acta Anaesthesiol Scand 1984; 28:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cold GE, Eskesen V, Eriksen H, et al. CBF and CMRO2 during continuous etomidate infusion supplemented with N2O and fentanyl in patients with supratentorial cerebral tumour. A dose-response study. Acta Anaesthesiol Scand 1985; 29:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modica PA, Tempelhoff R. Intracranial pressure during induction of anaesthesia and tracheal intubation with etomidate-induced EEG burst suppression. Can J Anaesth 1992; 39:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dearden NM, McDowall DG. Comparison of etomidate and althesin in the reduction of increased intracranial pressure after head injury. Br J Anaesth 1985; 57:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Archambault P, Dionne CE, Lortie G, et al. Adrenal inhibition following a single dose of etomidate in intubated traumatic brain injury victims. CJEM 2012; 14:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jong FH, Mallios C, Jansen C, et al. Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab 1984; 59:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drummond JC, Cole DJ, Patel PM. Etomidate, transfusion, and vasospasm. J Neurosurg 2005; 102:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milde LN, Milde JH, Michenfelder JD. Cerebral functional, metabolic, and hemodynamic effects of etomidate in dogs. Anesthesiology 1985; 63:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson SC, Brown P 3rd, Loftus CM. Effects of etomidate administration on cerebral collateral flow. Neurosurgery 1998; 43:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edelman GJ, Hoffman WE, Charbel FT. Cerebral hypoxia after etomidate administration and temporary cerebral artery occlusion. Anesth Analg 1997; 85:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabey PG, Smith G. Anaesthetic factors contributing to postoperative nausea and vomiting. Br J Anaesth 1992; 69:40S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camu F, Lauwers MH, Verbessem D. Incidence and aetiology of postoperative nausea and vomiting. Eur J Anaesthesiol Suppl 1992; 6:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dawson B, Michenfelder JD, Theye RA. Effects of ketamine on canine cerebral blood flow and metabolism: modification by prior administration of thiopental. Anesth Analg 1971; 50:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takeshita H, Okuda Y, Sari A. The effects of ketamine on cerebral circulation and metabolism in man. Anesthesiology 1972; 36:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hougaard K, Hansen A, Brodersen P. The effect of ketamine on regional cerebral blood flow in man. Anesthesiology 1974; 41:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sari A, Okuda Y, Takeshita H. The effect of ketamine on cerebrospinal fluid pressure. Anesth Analg 1972; 51:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wyte SR, Shapiro HM, Turner P, Harris AB. Ketamine-induced intracranial hypertension. Anesthesiology 1972; 36:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strebel S, Kaufmann M, Maître L, Schaefer HG. Effects of ketamine on cerebral blood flow velocity in humans. Influence of pretreatment with midazolam or esmolol. Anaesthesia 1995; 50:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albanèse J, Arnaud S, Rey M, et al. Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation. Anesthesiology 1997; 87:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayberg TS, Lam AM, Matta BF, et al. Ketamine does not increase cerebral blood flow velocity or intracranial pressure during isoflurane/nitrous oxide anesthesia in patients undergoing craniotomy. Anesth Analg 1995; 81:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeiler FA, Teitelbaum J, West M, Gillman LM. The ketamine effect on intracranial pressure in nontraumatic neurological illness. J Crit Care 2014; 29:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang X, Ding X, Tong Y, et al. Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials. J Anesth 2014; 28:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warner DS, Hindman BJ, Todd MM, et al. Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. Anesth Analg 1996; 83:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leone M, Albanèse J, Viviand X, et al. The effects of remifentanil on endotracheal suctioning-induced increases in intracranial pressure in head-injured patients. Anesth Analg 2004; 99:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egan TD. Pharmacokinetics and pharmacodynamics of remifentanil: an update in the year 2000. Curr Opin Anaesthesiol 2000; 13:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson JA, Gillespie JA. Tracheal intubation after induction of anaesthesia with propofol, alfentanil and i.v. lignocaine. Br J Anaesth 1993; 70:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           STEINHAUS JE, GASKIN L. A study of intravenous lidocaine as a suppressant of cough reflex. Anesthesiology 1963; 24:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarkkanen L, Laitinen L, Johansson G. Effects of d-tubocurarine on intracranial pressure and thalamic electrical impedance. Anesthesiology 1974; 40:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanier WL, Iaizzo PA, Milde JH, Sharbrough FW. The cerebral and systemic effects of movement in response to a noxious stimulus in lightly anesthetized dogs. Possible modulation of cerebral function by muscle afferents. Anesthesiology 1994; 80:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stirt JA, Grosslight KR, Bedford RF, Vollmer D. "Defasciculation" with metocurine prevents succinylcholine-induced increases in intracranial pressure. Anesthesiology 1987; 67:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Incorrect Units of Measure in a Table. JAMA 2023; 329:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sloan T. The incidence, volume, absorption, and timing of supratentorial pneumocephalus during posterior fossa neurosurgery conducted in the sitting position. J Neurosurg Anesthesiol 2010; 22:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biyani N, Silbiger A, Ben-Ari J, Constantini S. Postoperative brain stem tension pneumocephalus causing transient locked-in syndrome. Pediatr Neurosurg 2007; 43:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens QE, Colen CB, Ham SD, et al. Delayed lateral rectus palsy following resection of a pineal cyst in sitting position: direct or indirect compressive phenomenon? J Child Neurol 2007; 22:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Lorenzo N, Caruso R, Floris R, et al. Pneumocephalus and tension pneumocephalus after posterior fossa surgery in the sitting position: a prospective study. Acta Neurochir (Wien) 1986; 83:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scherer R, Van Aken H, Lawin P, Dorsic D. [Tension pneumocephalus. A frequently misconstrued complication following neurosurgical operations]. Neurochirurgia (Stuttg) 1984; 27:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toung T, Donham RT, Lehner A, et al. Tension pneumocephalus after posterior fossa craniotomy: report of four additional cases and review of postoperative pneumocephalus. Neurosurgery 1983; 12:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paisansathan C, Koenig HM, Wheeler PJ, et al. Loss of SSEP during sitting craniotomy. J Neurosurg Anesthesiol 2003; 15:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chui J, Mariappan R, Mehta J, et al. Comparison of propofol and volatile agents for maintenance of anesthesia during elective craniotomy procedures: systematic review and meta-analysis. Can J Anaesth 2014; 61:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Todd MM, Drummond JC. A comparison of the cerebrovascular and metabolic effects of halothane and isoflurane in the cat. Anesthesiology 1984; 60:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lutz LJ, Milde JH, Milde LN. The cerebral functional, metabolic, and hemodynamic effects of desflurane in dogs. Anesthesiology 1990; 73:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mielck F, Stephan H, Weyland A, Sonntag H. Effects of one minimum alveolar anesthetic concentration sevoflurane on cerebral metabolism, blood flow, and CO2 reactivity in cardiac patients. Anesth Analg 1999; 89:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ornstein E, Young WL, Fleischer LH, Ostapkovich N. Desflurane and isoflurane have similar effects on cerebral blood flow in patients with intracranial mass lesions. Anesthesiology 1993; 79:498.
          </a>
         </li>
         <li class="breakAll">
          Patel PM, Drummond JC, Lemkuil BP. Cerebral physiology and the effects of anesthetic drugs. In: Miller's Anesthesia, 8th ed, Miller RD, Cohen NH, Eriksson LI, et al (Eds), Philadelphia 2014. p.387.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bundgaard H, von Oettingen G, Larsen KM, et al. Effects of sevoflurane on intracranial pressure, cerebral blood flow and cerebral metabolism. A dose-response study in patients subjected to craniotomy for cerebral tumours. Acta Anaesthesiol Scand 1998; 42:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen TD, Warner DS, Todd MM, Vust LJ. The role of cerebral metabolism in determining the local cerebral blood flow effects of volatile anesthetics: evidence for persistent flow-metabolism coupling. J Cereb Blood Flow Metab 1989; 9:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaisti KK, Långsjö JW, Aalto S, et al. Effects of sevoflurane, propofol, and adjunct nitrous oxide on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003; 99:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madsen JB, Cold GE, Hansen ES, Bardrum B. The effect of isoflurane on cerebral blood flow and metabolism in humans during craniotomy for small supratentorial cerebral tumors. Anesthesiology 1987; 66:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinstrup P, Ryding E, Ohlsson T, et al. Cerebral blood volume (CBV) in humans during normo- and hypocapnia: influence of nitrous oxide (N(2)O). Anesthesiology 2001; 95:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Algotsson L, Messeter K, Rosén I, Holmin T. Effects of nitrous oxide on cerebral haemodynamics and metabolism during isoflurane anaesthesia in man. Acta Anaesthesiol Scand 1992; 36:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Field LM, Dorrance DE, Krzeminska EK, Barsoum LZ. Effect of nitrous oxide on cerebral blood flow in normal humans. Br J Anaesth 1993; 70:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henriksen HT, Jörgensen PB. The effect of nitrous oxide on intracranial pressure in patients with intracranial disorders. Br J Anaesth 1973; 45:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phirman JR, Shapiro HM. Modification of nitrous oxide-induced intracranial hypertension by prior induction of anesthesia. Anesthesiology 1977; 46:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misfeldt BB, Jörgensen PB, Rishöj M. The effect of nitrous oxide and halothane upon the intracranial pressure in hypocapnic patients with intracranial disorders. Br J Anaesth 1974; 46:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jobes DR, Kennell EM, Bush GL, et al. Cerebral blood flow and metabolism during morphine--nitrous oxide anesthesia in man. Anesthesiology 1977; 47:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eng C, Lam AM, Mayberg TS, et al. The influence of propofol with and without nitrous oxide on cerebral blood flow velocity and CO2 reactivity in humans. Anesthesiology 1992; 77:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasternak JJ, Lanier WL. Is nitrous oxide use appropriate in neurosurgical and neurologically at-risk patients? Curr Opin Anaesthesiol 2010; 23:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reasoner DK, Todd MM, Scamman FL, Warner DS. The incidence of pneumocephalus after supratentorial craniotomy. Observations on the disappearance of intracranial air. Anesthesiology 1994; 80:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaisti KK, Metsähonkala L, Teräs M, et al. Effects of surgical levels of propofol and sevoflurane anesthesia on cerebral blood flow in healthy subjects studied with positron emission tomography. Anesthesiology 2002; 96:1358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alkire MT, Haier RJ, Barker SJ, et al. Cerebral metabolism during propofol anesthesia in humans studied with positron emission tomography. Anesthesiology 1995; 82:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cenic A, Craen RA, Lee TY, Gelb AW. Cerebral blood volume and blood flow responses to hyperventilation in brain tumors during isoflurane or propofol anesthesia. Anesth Analg 2002; 94:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Todd MM, Warner DS, Sokoll MD, et al. A prospective, comparative trial of three anesthetics for elective supratentorial craniotomy. Propofol/fentanyl, isoflurane/nitrous oxide, and fentanyl/nitrous oxide. Anesthesiology 1993; 78:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cole CD, Gottfried ON, Gupta DK, Couldwell WT. Total intravenous anesthesia: advantages for intracranial surgery. Neurosurgery 2007; 61:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Shen J, Ge L, et al. Dexmedetomidine for craniotomy under general anesthesia: A systematic review and meta-analysis of randomized clinical trials. J Clin Anesth 2019; 54:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prielipp RC, Wall MH, Tobin JR, et al. Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow. Anesth Analg 2002; 95:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drummond JC, Dao AV, Roth DM, et al. Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans. Anesthesiology 2008; 108:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zornow MH, Fleischer JE, Scheller MS, et al. Dexmedetomidine, an alpha 2-adrenergic agonist, decreases cerebral blood flow in the isoflurane-anesthetized dog. Anesth Analg 1990; 70:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karlsson BR, Forsman M, Roald OK, et al. Effect of dexmedetomidine, a selective and potent alpha 2-agonist, on cerebral blood flow and oxygen consumption during halothane anesthesia in dogs. Anesth Analg 1990; 71:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zornow MH, Maze M, Dyck JB, Shafer SL. Dexmedetomidine decreases cerebral blood flow velocity in humans. J Cereb Blood Flow Metab 1993; 13:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drummond JC, Sturaitis MK. Brain tissue oxygenation during dexmedetomidine administration in surgical patients with neurovascular injuries. J Neurosurg Anesthesiol 2010; 22:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soriano SG, Martyn JA. Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance. Clin Pharmacokinet 2004; 43:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LASSEN NA. Cerebral blood flow and oxygen consumption in man. Physiol Rev 1959; 39:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of induced hypertension on intracranial pressure and flow velocities of the middle cerebral arteries in patients with large hemispheric stroke. Stroke 2002; 33:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czosnyka M, Smielewski P, Piechnik S, et al. Cerebral autoregulation following head injury. J Neurosurg 2001; 95:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dandona P, James IM, Newbury PA, et al. Cerebral blood flow in diabetes mellitus: evidence of abnormal cerebrovascular reactivity. Br Med J 1978; 2:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strandgaard S. Autoregulation of cerebral blood flow in hypertensive patients. The modifying influence of prolonged antihypertensive treatment on the tolerance to acute, drug-induced hypotension. Circulation 1976; 53:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma D, Bithal PK, Dash HH, et al. Cerebral autoregulation and CO2 reactivity before and after elective supratentorial tumor resection. J Neurosurg Anesthesiol 2010; 22:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sviri GE, Aaslid R, Douville CM, et al. Time course for autoregulation recovery following severe traumatic brain injury. J Neurosurg 2009; 111:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rangel-Castilla L, Gasco J, Nauta HJ, et al. Cerebral pressure autoregulation in traumatic brain injury. Neurosurg Focus 2008; 25:E7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogilvy CS, Chu D, Kaplan S. Mild hypothermia, hypertension, and mannitol are protective against infarction during experimental intracranial temporary vessel occlusion. Neurosurgery 1996; 38:1202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strebel SP, Kindler C, Bissonnette B, et al. The impact of systemic vasoconstrictors on the cerebral circulation of anesthetized patients. Anesthesiology 1998; 89:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavi S, Egbarya R, Lavi R, Jacob G. Role of nitric oxide in the regulation of cerebral blood flow in humans: chemoregulation versus mechanoregulation. Circulation 2003; 107:1901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schleien CL, Koehler RC, Gervais H, et al. Organ blood flow and somatosensory-evoked potentials during and after cardiopulmonary resuscitation with epinephrine or phenylephrine. Circulation 1989; 79:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bombardieri AM, Singh NP, Yaeger L, et al. The Regional Cerebral Oxygen Saturation Effect of Inotropes/Vasopressors Administered to Treat Intraoperative Hypotension: A Bayesian Network Meta-analysis. J Neurosurg Anesthesiol 2023; 35:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nissen P, Brassard P, Jørgensen TB, Secher NH. Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension. Neurocrit Care 2010; 12:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meng L, Cannesson M, Alexander BS, et al. Effect of phenylephrine and ephedrine bolus treatment on cerebral oxygenation in anaesthetized patients. Br J Anaesth 2011; 107:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brassard P, Seifert T, Wissenberg M, et al. Phenylephrine decreases frontal lobe oxygenation at rest but not during moderately intense exercise. J Appl Physiol (1985) 2010; 108:1472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucas SJ, Tzeng YC, Galvin SD, et al. Influence of changes in blood pressure on cerebral perfusion and oxygenation. Hypertension 2010; 55:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sørensen H, Rasmussen P, Siebenmann C, et al. Extra-cerebral oxygenation influence on near-infrared-spectroscopy-determined frontal lobe oxygenation in healthy volunteers: a comparison between INVOS-4100 and NIRO-200NX. Clin Physiol Funct Imaging 2015; 35:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch KU, Mikkelsen IK, Aanerud J, et al. Ephedrine versus Phenylephrine Effect on Cerebral Blood Flow and Oxygen Consumption in Anesthetized Brain Tumor Patients: A Randomized Clinical Trial. Anesthesiology 2020; 133:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch KU, Mikkelsen IK, Espelund US, et al. Cerebral Macro- and Microcirculation during Ephedrine versus Phenylephrine Treatment in Anesthetized Brain Tumor Patients: A Randomized Clinical Trial Using Magnetic Resonance Imaging. Anesthesiology 2021; 135:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez SJ, Barakat I, Ziogas J, et al. Association of copeptin, a surrogate marker of arginine vasopressin, with cerebral vasospasm and delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage. J Neurosurg 2018; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brassard P, Seifert T, Secher NH. Is cerebral oxygenation negatively affected by infusion of norepinephrine in healthy subjects? Br J Anaesth 2009; 102:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schroeder T, Schierbeck J, Howardy P, et al. Effect of labetalol on cerebral blood flow and middle cerebral arterial flow velocity in healthy volunteers. Neurol Res 1991; 13:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shenkin HA, Bezier HS, Bouzarth WF. Restricted fluid intake. Rational management of the neurosurgical patient. J Neurosurg 1976; 45:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Todd MM, Tommasino C, Moore S. Cerebral effects of isovolemic hemodilution with a hypertonic saline solution. J Neurosurg 1985; 63:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lescot T, Degos V, Zouaoui A, et al. Opposed effects of hypertonic saline on contusions and noncontused brain tissue in patients with severe traumatic brain injury. Crit Care Med 2006; 34:3029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kellum JA. Saline-induced hyperchloremic metabolic acidosis. Crit Care Med 2002; 30:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SAFE Study Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australian Red Cross Blood Service, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007; 357:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg 2008; 107:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitesell R, Asiddao C, Gollman D, Jablonski J. Relationship between arterial and peak expired carbon dioxide pressure during anesthesia and factors influencing the difference. Anesth Analg 1981; 60:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wahba RW, Tessler MJ. Misleading end-tidal CO2 tensions. Can J Anaesth 1996; 43:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelb AW, Craen RA, Rao GS, et al. Does hyperventilation improve operating condition during supratentorial craniotomy? A multicenter randomized crossover trial. Anesth Analg 2008; 106:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coles JP, Fryer TD, Coleman MR, et al. Hyperventilation following head injury: effect on ischemic burden and cerebral oxidative metabolism. Crit Care Med 2007; 35:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prabhakar H, Singh GP, Anand V, Kalaivani M. Mannitol versus hypertonic saline for brain relaxation in patients undergoing craniotomy. Cochrane Database Syst Rev 2014; :CD010026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rozet I, Tontisirin N, Muangman S, et al. Effect of equiosmolar solutions of mannitol versus hypertonic saline on intraoperative brain relaxation and electrolyte balance. Anesthesiology 2007; 107:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang J, Yang Y, Wang W, et al. Comparison of equiosmolar hypertonic saline and mannitol for brain relaxation during craniotomies: A meta-analysis of randomized controlled trials. Neurosurg Rev 2018; 41:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdulhamid AS, Ghaddaf AA, Bokhari AF, et al. Equiosmolar hypertonic saline and mannitol for brain relaxation in patients undergoing supratentorial tumor surgery: A systematic review and meta-analysis. Surg Neurol Int 2022; 13:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suh SW, Hamby AM, Swanson RA. Hypoglycemia, brain energetics, and hypoglycemic neuronal death. Glia 2007; 55:1280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma D, Jelacic J, Chennuri R, et al. Incidence and risk factors for perioperative hyperglycemia in children with traumatic brain injury. Anesth Analg 2009; 108:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeremitsky E, Omert LA, Dunham CM, et al. The impact of hyperglycemia on patients with severe brain injury. J Trauma 2005; 58:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu-DeRyke X, Collingridge DS, Orme J, et al. Clinical impact of early hyperglycemia during acute phase of traumatic brain injury. Neurocrit Care 2009; 11:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherian L, Hannay HJ, Vagner G, et al. Hyperglycemia increases neurological damage and behavioral deficits from post-traumatic secondary ischemic insults. J Neurotrauma 1998; 15:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam AM, Winn HR, Cullen BF, Sundling N. Hyperglycemia and neurological outcome in patients with head injury. J Neurosurg 1991; 75:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gruenbaum SE, Toscani L, Fomberstein KM, et al. Severe Intraoperative Hyperglycemia Is Independently Associated With Postoperative Composite Infection After Craniotomy: An Observational Study. Anesth Analg 2017; 125:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulikov A, Krovko Y, Nikitin A, et al. Severe Intraoperative Hyperglycemia and Infectious Complications After Elective Brain Neurosurgical Procedures: Prospective Observational Study. Anesth Analg 2022; 135:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cai YH, Zeng HY, Shi ZH, et al. Factors influencing delayed extubation after infratentorial craniotomy for tumour resection: a prospective cohort study of 800 patients in a Chinese neurosurgical centre. J Int Med Res 2013; 41:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cata JP, Saager L, Kurz A, Avitsian R. Successful extubation in the operating room after infratentorial craniotomy: the Cleveland Clinic experience. J Neurosurg Anesthesiol 2011; 23:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flexman AM, Merriman B, Griesdale DE, et al. Infratentorial neurosurgery is an independent risk factor for respiratory failure and death in patients undergoing intracranial tumor resection. J Neurosurg Anesthesiol 2014; 26:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basali A, Mascha EJ, Kalfas I, Schubert A. Relation between perioperative hypertension and intracranial hemorrhage after craniotomy. Anesthesiology 2000; 93:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jian M, Li X, Wang A, et al. Flurbiprofen and hypertension but not hydroxyethyl starch are associated with post-craniotomy intracranial haematoma requiring surgery. Br J Anaesth 2014; 113:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bijker JB, Gelb AW. Review article: the role of hypotension in perioperative stroke. Can J Anaesth 2013; 60:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kross RA, Ferri E, Leung D, et al. A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. Anesth Analg 2000; 91:904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thal GD, Szabo MD, Lopez-Bresnahan M, Crosby G. Exacerbation or unmasking of focal neurologic deficits by sedatives. Anesthesiology 1996; 85:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubow J, Bernstein RA. Amplification of acute focal ischemic deficit by narcotics. Neurocrit Care 2008; 8:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazar RM, Fitzsimmons BF, Marshall RS, et al. Reemergence of stroke deficits with midazolam challenge. Stroke 2002; 33:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazar RM, Fitzsimmons BF, Marshall RS, et al. Midazolam challenge reinduces neurological deficits after transient ischemic attack. Stroke 2003; 34:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin N, Han R, Zhou J, Gelb AW. Mild Sedation Exacerbates or Unmasks Focal Neurologic Dysfunction in Neurosurgical Patients with Supratentorial Brain Mass Lesions in a Drug-specific Manner. Anesthesiology 2016; 124:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin N, Han R, Hui X, et al. Midazolam Sedation Induces Upper Limb Coordination Deficits That Are Reversed by Flumazenil in Patients with Eloquent Area Gliomas. Anesthesiology 2019; 131:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhondali O, Genty C, Halle C, et al. Do patients still require admission to an intensive care unit after elective craniotomy for brain surgery? J Neurosurg Anesthesiol 2011; 23:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young JS, Chan AK, Viner JA, et al. A Safe Transitions Pathway for post-craniotomy neurological surgery patients: high-value care that bypasses the intensive care unit. J Neurosurg 2020; 134:1386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottschalk A, Berkow LC, Stevens RD, et al. Prospective evaluation of pain and analgesic use following major elective intracranial surgery. J Neurosurg 2007; 106:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Benedittis G, Lorenzetti A, Migliore M, et al. Postoperative pain in neurosurgery: a pilot study in brain surgery. Neurosurgery 1996; 38:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thibault M, Girard F, Moumdjian R, et al. Craniotomy site influences postoperative pain following neurosurgical procedures: a retrospective study. Can J Anaesth 2007; 54:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaur A, Selwa L, Fromes G, Ross DA. Persistent headache after supratentorial craniotomy. Neurosurgery 2000; 47:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Driscoll CL, Beatty CW. Pain after acoustic neuroma surgery. Otolaryngol Clin North Am 1997; 30:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stumpo V, Staartjes VE, Quddusi A, et al. Enhanced Recovery After Surgery strategies for elective craniotomy: a systematic review. J Neurosurg 2021; 135:1857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galvin IM, Levy R, Day AG, Gilron I. Pharmacological interventions for the prevention of acute postoperative pain in adults following brain surgery. Cochrane Database Syst Rev 2019; 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigamonti A, Garavaglia MM, Ma K, et al. Effect of bilateral scalp nerve blocks on postoperative pain and discharge times in patients undergoing supratentorial craniotomy and general anesthesia: a randomized-controlled trial. Can J Anaesth 2020; 67:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudray E, N' Guyen C, Martin E, et al. Efficacy of scalp nerve blocks using ropivacaïne 0,75% associated with intravenous dexamethasone for postoperative pain relief in craniotomies. Clin Neurol Neurosurg 2020; 197:106125.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 93391 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21730309" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Development and validation of a risk calculator for prediction of cardiac risk after surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21757571" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Development and validation of a risk calculator predicting postoperative respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9585285" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clonidine premedication decreases hemodynamic responses to pin head-holder application during craniotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18580347" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Dexmedetomidine attenuates the hemodynamic and neuroendocrinal responses to skull-pin head-holder application during craniotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10213433" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Effects of two calculated plasma sufentanil concentrations on the hemodynamic and bispectral index responses to Mayfield head holder application.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24161010" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A novel application for bolus remifentanil: blunting the hemodynamic response to Mayfield skull clamp placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27996204" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Postoperative Pain Control Following Craniotomy: A Systematic Review of Recent Clinical Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23477962" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Regional scalp block for postcraniotomy analgesia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33060491" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Influence of Levobupivacaine Regional Scalp Block on Hemodynamic Stability, Intra- and Postoperative Opioid Consumption in Supratentorial Craniotomies: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3259095" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effect of propofol on cerebral blood flow and metabolism in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12552189" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Intracranial pressure and cerebral hemodynamic in patients with cerebral tumors: a randomized prospective study of patients subjected to craniotomy in propofol-fentanyl, isoflurane-fentanyl, or sevoflurane-fentanyl anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1519782" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The responsiveness of cerebral blood flow to changes in arterial carbon dioxide is maintained during propofol-nitrous oxide anesthesia in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2034348" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Differential effects of pentobarbital on intracerebral arterioles and venules of rats in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4854910" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The interdependency of cerebral functional and metabolic effects following massive doses of thiopental in the dog.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6496004" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Minimum cerebral blood flow and metabolism during craniotomy. Effect of thiopental loading.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3929551" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : CBF and CMRO2 during continuous etomidate infusion supplemented with N2O and fentanyl in patients with supratentorial cerebral tumour. A dose-response study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1551154" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Intracranial pressure during induction of anaesthesia and tracheal intubation with etomidate-induced EEG burst suppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3885982" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Comparison of etomidate and althesin in the reduction of increased intracranial pressure after head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22967694" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Adrenal inhibition following a single dose of etomidate in intubated traumatic brain injury victims.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6092411" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15796403" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Etomidate, transfusion, and vasospasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3929648" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cerebral functional, metabolic, and hemodynamic effects of etomidate in dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9696085" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effects of etomidate administration on cerebral collateral flow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9322462" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Cerebral hypoxia after etomidate administration and temporary cerebral artery occlusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1486013" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Anaesthetic factors contributing to postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1425622" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Incidence and aetiology of postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5103782" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effects of ketamine on canine cerebral blood flow and metabolism: modification by prior administration of thiopental.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5006989" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The effects of ketamine on cerebral circulation and metabolism in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4372911" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The effect of ketamine on regional cerebral blood flow in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5064788" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The effect of ketamine on cerebrospinal fluid pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Ketamine-induced intracranial hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7717488" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Effects of ketamine on cerebral blood flow velocity in humans. Influence of pretreatment with midazolam or esmolol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9416717" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7598288" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Ketamine does not increase cerebral blood flow velocity or intracranial pressure during isoflurane/nitrous oxide anesthesia in patients undergoing craniotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24996763" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The ketamine effect on intracranial pressure in nontraumatic neurological illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24859931" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8694317" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15385374" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The effects of remifentanil on endotracheal suctioning-induced increases in intracranial pressure in head-injured patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17016340" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pharmacokinetics and pharmacodynamics of remifentanil: an update in the year 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8435260" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Tracheal intubation after induction of anaesthesia with propofol, alfentanil and i.v. lignocaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13983769" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A study of intravenous lidocaine as a suppressant of cough reflex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4592211" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effects of d-tubocurarine on intracranial pressure and thalamic electrical impedance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8311321" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The cerebral and systemic effects of movement in response to a noxious stimulus in lightly anesthetized dogs. Possible modulation of cerebral function by muscle afferents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3605735" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : "Defasciculation" with metocurine prevents succinylcholine-induced increases in intracranial pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36786804" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Incorrect Units of Measure in a Table.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19779366" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The incidence, volume, absorption, and timing of supratentorial pneumocephalus during posterior fossa neurosurgery conducted in the sitting position.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17786010" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Postoperative brain stem tension pneumocephalus causing transient locked-in syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18174563" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Delayed lateral rectus palsy following resection of a pineal cyst in sitting position: direct or indirect compressive phenomenon?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3812035" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Pneumocephalus and tension pneumocephalus after posterior fossa surgery in the sitting position: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6738774" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : [Tension pneumocephalus. A frequently misconstrued complication following neurosurgical operations].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6835498" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Tension pneumocephalus after posterior fossa craniotomy: report of four additional cases and review of postoperative pneumocephalus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14508175" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Loss of SSEP during sitting craniotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24482247" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Comparison of propofol and volatile agents for maintenance of anesthesia during elective craniotomy procedures: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6703382" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A comparison of the cerebrovascular and metabolic effects of halothane and isoflurane in the cat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2360723" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The cerebral functional, metabolic, and hemodynamic effects of desflurane in dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10439749" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effects of one minimum alveolar anesthetic concentration sevoflurane on cerebral metabolism, blood flow, and CO2 reactivity in cardiac patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8363075" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Desflurane and isoflurane have similar effects on cerebral blood flow in patients with intracranial mass lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8363075" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Desflurane and isoflurane have similar effects on cerebral blood flow in patients with intracranial mass lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9689265" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Effects of sevoflurane on intracranial pressure, cerebral blood flow and cerebral metabolism. A dose-response study in patients subjected to craniotomy for cerebral tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2715204" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The role of cerebral metabolism in determining the local cerebral blood flow effects of volatile anesthetics: evidence for persistent flow-metabolism coupling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12960544" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Effects of sevoflurane, propofol, and adjunct nitrous oxide on regional cerebral blood flow, oxygen consumption, and blood volume in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3826691" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The effect of isoflurane on cerebral blood flow and metabolism in humans during craniotomy for small supratentorial cerebral tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11684974" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cerebral blood volume (CBV) in humans during normo- and hypocapnia: influence of nitrous oxide (N(2)O).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1539478" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effects of nitrous oxide on cerebral haemodynamics and metabolism during isoflurane anaesthesia in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8435258" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effect of nitrous oxide on cerebral blood flow in normal humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4715597" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The effect of nitrous oxide on intracranial pressure in patients with intracranial disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/835849" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Modification of nitrous oxide-induced intracranial hypertension by prior induction of anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4621214" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The effect of nitrous oxide and halothane upon the intracranial pressure in hypocapnic patients with intracranial disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/869245" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Cerebral blood flow and metabolism during morphine--nitrous oxide anesthesia in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1443739" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The influence of propofol with and without nitrous oxide on cerebral blood flow velocity and CO2 reactivity in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20689409" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Is nitrous oxide use appropriate in neurosurgical and neurologically at-risk patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8017640" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The incidence of pneumocephalus after supratentorial craniotomy. Observations on the disappearance of intracranial air.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12170048" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effects of surgical levels of propofol and sevoflurane anesthesia on cerebral blood flow in healthy subjects studied with positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7856898" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Cerebral metabolism during propofol anesthesia in humans studied with positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11867393" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Cerebral blood volume and blood flow responses to hyperventilation in brain tumors during isoflurane or propofol anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8512094" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A prospective, comparative trial of three anesthetics for elective supratentorial craniotomy. Propofol/fentanyl, isoflurane/nitrous oxide, and fentanyl/nitrous oxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18091252" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Total intravenous anesthesia: advantages for intracranial surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30445412" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Dexmedetomidine for craniotomy under general anesthesia: A systematic review and meta-analysis of randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12351293" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18212567" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1971500" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Dexmedetomidine, an alpha 2-adrenergic agonist, decreases cerebral blood flow in the isoflurane-anesthetized dog.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1973880" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Effect of dexmedetomidine, a selective and potent alpha 2-agonist, on cerebral blood flow and oxygen consumption during halothane anesthesia in dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8094720" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Dexmedetomidine decreases cerebral blood flow velocity in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20622684" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Brain tissue oxygenation during dexmedetomidine administration in surgical patients with neurovascular injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14748617" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13645234" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Cerebral blood flow and oxygen consumption in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11935051" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effects of induced hypertension on intracranial pressure and flow velocities of the middle cerebral arteries in patients with large hemispheric stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11702864" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Cerebral autoregulation following head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/687900" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Cerebral blood flow in diabetes mellitus: evidence of abnormal cerebrovascular reactivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/815061" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Autoregulation of cerebral blood flow in hypertensive patients. The modifying influence of prolonged antihypertensive treatment on the tolerance to acute, drug-induced hypotension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20308819" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Cerebral autoregulation and CO2 reactivity before and after elective supratentorial tumor resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19392589" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Time course for autoregulation recovery following severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18828705" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Cerebral pressure autoregulation in traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8727152" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Mild hypothermia, hypertension, and mannitol are protective against infarction during experimental intracranial temporary vessel occlusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9667295" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The impact of systemic vasoconstrictors on the cerebral circulation of anesthetized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12665500" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Role of nitric oxide in the regulation of cerebral blood flow in humans: chemoregulation versus mechanoregulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2720932" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Organ blood flow and somatosensory-evoked potentials during and after cardiopulmonary resuscitation with epinephrine or phenylephrine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34116546" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : The Regional Cerebral Oxygen Saturation Effect of Inotropes/Vasopressors Administered to Treat Intraoperative Hypotension: A Bayesian Network Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19957053" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21642644" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Effect of phenylephrine and ephedrine bolus treatment on cerebral oxygenation in anaesthetized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20223999" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Phenylephrine decreases frontal lobe oxygenation at rest but not during moderately intense exercise.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20083726" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Influence of changes in blood pressure on cerebral perfusion and oxygenation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24618369" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Extra-cerebral oxygenation influence on near-infrared-spectroscopy-determined frontal lobe oxygenation in healthy volunteers: a comparison between INVOS-4100 and NIRO-200NX.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32482999" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Ephedrine versus Phenylephrine Effect on Cerebral Blood Flow and Oxygen Consumption in Anesthetized Brain Tumor Patients: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34344019" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Cerebral Macro- and Microcirculation during Ephedrine versus Phenylephrine Treatment in Anesthetized Brain Tumor Patients: A Randomized Clinical Trial Using Magnetic Resonance Imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29726784" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Association of copeptin, a surrogate marker of arginine vasopressin, with cerebral vasospasm and delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19376788" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Is cerebral oxygenation negatively affected by infusion of norepinephrine in healthy subjects?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1675440" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Effect of labetalol on cerebral blood flow and middle cerebral arterial flow velocity in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/956879" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Restricted fluid intake. Rational management of the neurosurgical patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4056907" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Cerebral effects of isovolemic hemodilution with a hypertonic saline solution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16971850" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Opposed effects of hypertonic saline on contusions and noncontused brain tissue in patients with severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11902280" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Saline-induced hyperchloremic metabolic acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17761591" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Saline or albumin for fluid resuscitation in patients with traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18633012" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6787952" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Relationship between arterial and peak expired carbon dioxide pressure during anesthesia and factors influencing the difference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8840067" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Misleading end-tidal CO2 tensions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18227320" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Does hyperventilation improve operating condition during supratentorial craniotomy? A multicenter randomized crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17205016" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Hyperventilation following head injury: effect on ischemic burden and cerebral oxidative metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25019296" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Mannitol versus hypertonic saline for brain relaxation in patients undergoing craniotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18073543" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Effect of equiosmolar solutions of mannitol versus hypertonic saline on intraoperative brain relaxation and electrolyte balance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28258418" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Comparison of equiosmolar hypertonic saline and mannitol for brain relaxation during craniotomies: A meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35509546" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Equiosmolar hypertonic saline and mannitol for brain relaxation in patients undergoing supratentorial tumor surgery: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17659530" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Hypoglycemia, brain energetics, and hypoglycemic neuronal death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19095835" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Incidence and risk factors for perioperative hyperglycemia in children with traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15674149" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : The impact of hyperglycemia on patients with severe brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19479209" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Clinical impact of early hyperglycemia during acute phase of traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9605346" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Hyperglycemia increases neurological damage and behavioral deficits from post-traumatic secondary ischemic insults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1885972" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Hyperglycemia and neurological outcome in patients with head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28181933" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Severe Intraoperative Hyperglycemia Is Independently Associated With Postoperative Composite Infection After Craniotomy: An Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35051950" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Severe Intraoperative Hyperglycemia and Infectious Complications After Elective Brain Neurosurgical Procedures: Prospective Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23569147" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Factors influencing delayed extubation after infratentorial craniotomy for tumour resection: a prospective cohort study of 800 patients in a Chinese neurosurgical centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21252705" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Successful extubation in the operating room after infratentorial craniotomy: the Cleveland Clinic experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23933960" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Infratentorial neurosurgery is an independent risk factor for respiratory failure and death in patients undergoing intracranial tumor resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10861145" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Relation between perioperative hypertension and intracranial hemorrhage after craniotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24966149" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Flurbiprofen and hypertension but not hydroxyethyl starch are associated with post-craniotomy intracranial haematoma requiring surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23239486" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Review article: the role of hypotension in perioperative stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11004045" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8694368" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Exacerbation or unmasking of focal neurologic deficits by sedatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18080807" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Amplification of acute focal ischemic deficit by narcotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11779924" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Reemergence of stroke deficits with midazolam challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12624310" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Midazolam challenge reinduces neurological deficits after transient ischemic attack.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26756518" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Mild Sedation Exacerbates or Unmasks Focal Neurologic Dysfunction in Neurosurgical Patients with Supratentorial Brain Mass Lesions in a Drug-specific Manner.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31094751" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Midazolam Sedation Induces Upper Limb Coordination Deficits That Are Reversed by Flumazenil in Patients with Eloquent Area Gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21270644" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Do patients still require admission to an intensive care unit after elective craniotomy for brain surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32470928" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : A Safe Transitions Pathway for post-craniotomy neurological surgery patients: high-value care that bypasses the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17410701" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Prospective evaluation of pain and analgesic use following major elective intracranial surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8837797" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Postoperative pain in neurosurgery: a pilot study in brain surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17602040" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Craniotomy site influences postoperative pain following neurosurgical procedures: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10981750" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Persistent headache after supratentorial craniotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9295259" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Pain after acoustic neuroma surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33962374" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Enhanced Recovery After Surgery strategies for elective craniotomy: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31747720" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Pharmacological interventions for the prevention of acute postoperative pain in adults following brain surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31879855" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Effect of bilateral scalp nerve blocks on postoperative pain and discharge times in patients undergoing supratentorial craniotomy and general anesthesia: a randomized-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32836063" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Efficacy of scalp nerve blocks using ropivacaïne 0,75% associated with intravenous dexamethasone for postoperative pain relief in craniotomies.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
